var title_f0_61_976="Algorithm treatment HBV children";
var content_f0_61_976=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 622px\">",
"   <div class=\"ttl\">",
"    Algorithm for selection of children for HBV antiviral treatment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 602px; height: 433px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HBV: hepatitis B virus; HBsAg: hepatitis B s antigen; ALT: alanine aminotransferase; HBeAg: hepatitis B e antigen; HCC: hepatocellular carcinoma; IU: international unit.",
"     <br>",
"      * The upper limit of normal (ULN) for ALT in children is not well established; it varies with the testing laboratory and the age of the child. For the purposes of HBV monitoring, we suggest that a child's ALT be considered elevated if it is greater than the ULN established by the testing laboratory, or &gt;40 IU/L, whichever is lower. For older adolescents, we suggest using 30 IU/L for males and 19 IU/L for females (the same ULN used for adults).",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Because of limited options with current drugs, it may be appropriate to treat older adolescents with immune active HBV with one of these newer agents using adult protocols, or to enroll children in clinical trials of newer agents, or even withhold treatment until the patient is old enough to be treated as adults (if liver fibrosis is only mild).",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Jonas MM, Block JM, Haber BA, et al. Treatment of children with chronic hepatitis B virus infection in the United States: Patient selection and therapeutic options. Hepatology 2010. Copyright &copy; 2010 American Association for the Study of Liver Diseases. Reproduced with permission from John Wiley &amp; Sons.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_61_976=[""].join("\n");
var outline_f0_61_976=null;
var title_f0_61_977="Crowing rooster maneuver";
var content_f0_61_977=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F80833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F80833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Crowing rooster maneuver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The crowing rooster maneuver is performed with the physician standing behind the patient, and exerting traction on the upper arms by pulling them backward and slightly superiorly. Both of these maneuvers may be done at the same time as neck extension or rotation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_61_977=[""].join("\n");
var outline_f0_61_977=null;
var title_f0_61_978="Volar displaced fx";
var content_f0_61_978=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Displaced volar fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Reverse bayonet. Panel A) Typical volar bayonet fracture. Often the distal end of the proximal fragment is buttonholed through the extensor tendons (arrows). (Copyright &copy; 1994 American Academy of Orthopaedic Surgeons. Reprinted from Operative Management of Upper Extremity Fractures in Children p.27 with permission.) Panel B) Intact volar periosteum and disrupted dorsal periosteum (arrows). The extensor tendons are displaced to either side of the proximal fragment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Waters PM, Mih AD. Fractures of the distal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_61_978=[""].join("\n");
var outline_f0_61_978=null;
var title_f0_61_979="Clonorchiasis adult";
var content_f0_61_979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Clonorchiasis adult",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Adult of",
"    <em>",
"     C. sinensis",
"    </em>",
"    .",
"    <br>",
"     (B) Adult of",
"     <em>",
"      C. sinensis",
"     </em>",
"     stained with carmine. Clearly visible in this image are the oral sucker (OS), pharynx (PH), ceca (CE), acetabulum, or ventral sucker (AC), uterus (UT), vitellaria (VT), and testes (TE).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Clonorchiasis. Available at:",
"      <a href=\"file://dpd.cdc.gov/dpdx/html/Clonorchiasis.htm\" target=\"_blank\">",
"       file://dpd.cdc.gov/dpdx/html/Clonorchiasis.htm",
"      </a>",
"      .",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_61_979=[""].join("\n");
var outline_f0_61_979=null;
var title_f0_61_980="Transient dilation pharm stress";
var content_f0_61_980=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transient ischemic LV dilatation during pharmacologic stress",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stress images demonstrate reversible anterior and inferior perfusion abnormalities (red arrow). The short axis images demonstrate transient ischemic left ventricular (LV) dilatation, which is associated with higher cardiac events.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Muthu Velusamy, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_61_980=[""].join("\n");
var outline_f0_61_980=null;
var title_f0_61_981="Spirometry PI";
var content_f0_61_981=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F84004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F84004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 515px\">",
"   <div class=\"ttl\">",
"    Spirometry (breathing test)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 495px; height: 434px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Spirometry is a breathing test that measures how well the lungs are working. It involves breathing in as deeply as you can, and then breathing out fast and hard into a mouthpiece. The mouthpiece is attached to a machine called a \"spirometer\".",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart Lung and Blood Institute. Types of Lung Function Tests: Spirometry.",
"     <a href=\"file://www.nhlbi.nih.gov/health/health-topics/topics/lft/types.html\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      file://www.nhlbi.nih.gov/health/health-topics/topics/lft/types.html",
"     </a>",
"     (Accessed June 19, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_61_981=[""].join("\n");
var outline_f0_61_981=null;
var title_f0_61_982="Saphenous vein cutdown dissection and cannulation";
var content_f0_61_982=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Saphenous vein cutdown: dissection and cannulation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 558px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Isolate the saphenous vein by blunt dissection using a curved hemostat (proximal to distal, paralleling the course of the vein). Take care to separate the vein from the surrounding tissue because a sensory nerve is located just anterior to it. Place a small silk suture around the distal end of the vein and anchor it with a clamp. B) Apply traction to the vein with the distal suture. Insert the point of a No. 11 scalpel blade into the upper third of the vessel perpendicular to the long axis of the vein to produce a flap halfway through the vein. C) Hold the vein flap open with a curved hook. Insert a beveled catheter into the vein opening. D) Advance the catheter into the vein. The catheter may be easier to advance when fluid is running through it.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_61_982=[""].join("\n");
var outline_f0_61_982=null;
var title_f0_61_983="Cardiac resynchronization therapy in atrial fibrillation";
var content_f0_61_983=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiac resynchronization therapy in atrial fibrillation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/61/983/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/61/983/contributors\">",
"     Leslie A Saxon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/61/983/contributors\">",
"     Michael Cao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/61/983/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/61/983/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/61/983/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/61/983/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/61/983/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/61/983/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with significant dyssynchrony due to intrinsic conduction disease, cardiac resynchronization therapy (CRT) with biventricular (BiV) pacing can improve ventricular synchrony. This is accomplished with an additional pacemaker lead implanted on the lateral left ventricle via a coronary vein. Among selected patients with HF who are in sinus rhythm, CRT improves cardiac performance, symptoms, and overall survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of atrial fibrillation (AF) in patients with heart failure varies with severity, ranging from 5 percent in patients with NYHA functional class I HF to 40 percent in patients with NYHA class IV HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/1\">",
"     1",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The use of CRT in patients with AF will be reviewed here. The general use of CRT in patients in sinus rhythm and the rationale for and mechanisms of benefit of CRT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10823?source=see_link\">",
"     \"Rationale for and mechanisms of benefit of cardiac resynchronization therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     USE OF CRT IN AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with chronic AF, CRT may be considered in two settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with AF who have an indication for atrioventricular (AV) node ablation for the purpose of definitive rate control may, via CRT, avoid the negative effects of dyssynchrony that can be induced by right ventricular pacing.",
"     </li>",
"     <li>",
"      Patients with AF who have HF may benefit from CRT. In this setting, AV node ablation appears to promote the efficacy of CRT by eliminating native AV conduction, thereby ensuring almost 100 percent biventricular pacing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Patients with an indication for AV node ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common nonpharmacologic method of ventricular rate control in AF is catheter-based radiofrequency ablation (RFA) of the AV node",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the His bundle. Because of the invasive nature of the procedure and the associated requirement for permanent pacemaker implantation, this treatment is generally reserved for patients in whom pharmacologic rate control therapy is either unsuccessful or not tolerated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of well-selected patients improve hemodynamically following AV junction ablation and standard right ventricular (RV) pacing. However, RV pacing causes the RV to contract before the LV (interventricular dyssynchrony), causing the septum to contract before the lateral wall (intraventricular dyssynchrony). Thus, ventricular pacing can induce ventricular dyssynchrony [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], which may impair LV systolic function, reduce functional status, and increase mortality. Patients with moderate or severe mitral regurgitation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    LV dysfunction appear to be at the highest risk of clinical deterioration with RV pacing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31510?source=see_link\">",
"     \"Overview of cardiac pacing in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These observations provide the rationale for prophylactic CRT in patients with AF who are undergoing AV node ablation. Observational studies and small randomized trials support the value of CRT in this setting, particularly for patients with reduced LV systolic function or heart failure (HF) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the randomized PAVE trial, 184 patients with chronic AF (83 percent with NYHA class II or III HF) underwent AV node ablation to treat medically refractory rapid ventricular rates and were randomly assigned to standard RV pacing or CRT [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/6\">",
"     6",
"    </a>",
"    ]. At six month follow-up, the following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CRT resulted in significantly greater post-ablation increases in six-minute walking distance, peak oxygen consumption with exercise, and exercise duration compared to standard RV pacing (31 versus 24 percent improvement, respectively).",
"     </li>",
"     <li>",
"      CRT resulted in preservation of the left ventricular ejection fraction (LVEF) which was significantly greater than in patients treated with RV pacing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The benefits of CRT were more prominent in patients with an LVEF &le;45 percent or with NYHA class II or III HF, compared to patients with less severe disease as manifested by a higher LVEF or NYHA class I HF.",
"   </p>",
"   <p>",
"    Based upon these observations, a CRT system was approved by the United States Food and Drug Administration in patients who have undergone AV node ablation and have NYHA class II or III HF [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patients with heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on CRT in patients with AF and heart failure (HF) are limited and have not proven the efficacy of CRT in this setting. Patients with atrial arrhythmias were excluded from the major CRT trials, such as CARE-HF and COMPANION [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/8\">",
"     8",
"    </a>",
"    ]. However, observational studies and a small randomized crossover trial suggest a benefit from CRT in AF patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. In addition, in the CARE-HF trial, while mortality was higher for patients who developed AF, these patients still benefitted from CRT for all major study end points [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of observational data from five studies (four prospective cohort studies and the MUSTIC randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/11\">",
"     11",
"    </a>",
"    ]) compared responses to CRT in 797 patients in sinus rhythm and 367 patients in AF [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/9\">",
"     9",
"    </a>",
"    ]. The overall use of AV node ablation was 56 percent. The NYHA functional class improved similarly for both groups although relative improvements in the 6 minute walk test and Minnesota score were greater in sinus rhythm patients than AF patients.",
"   </p>",
"   <p>",
"    In 2011, a meta-analysis of 23 studies reported that patients with atrial fibrillation had higher rates of clinical non-response to CRT (34.5 versus 26.7 percent) and higher mortality rates after CRT placement than patients with sinus rhythm. This meta-analysis was based on observations in a total of 7495 CRT recipients, 25.5 percent of whom had atrial fibrillation, and who were followed for a mean of 33 months. The presence of atrial fibrillation was associated with less improvement in quality of life, six-minute hall walk distance, and LV end-systolic volume but not LV ejection fraction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The MUSTIC AF trial was not included in the meta-analysis since it did not include patients in sinus rhythm. This study included 59 patients with HF and chronic AF with wide QRS complex who required a permanent pacemaker because of a slow ventricular rate; the patients were randomly assigned to either single site right ventricular (RV) pacing or biventricular (BiV) pacing in a crossover fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Sixty-three percent of AF patients had undergone AV node ablation.",
"   </p>",
"   <p>",
"    Only 39 patients completed the six month crossover trial, which limits any conclusions that can be drawn [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/10\">",
"     10",
"    </a>",
"    ]. Using an intention-to-treat analysis, there were no significant differences in exercise tolerance or peak oxygen consumption. In contrast, when data from the 37 patients who received effective therapy (97 to 100 percent paced cycles) were evaluated, BiV pacing was associated with a significant increase in six minute walk distance and peak oxygen consumption.",
"   </p>",
"   <p>",
"    In the RAFT trial, patients with permanent AF were randomly assigned to receive either an implantable cardioverter defibrillator (ICD, n = 115) or cardiac resynchronization combined with an implantable cardioverter defibrillator (CRT-D, n = 114) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/16\">",
"     16",
"    </a>",
"    ]. The ICD and CRT-D groups were comparable in age (mean 70 and 72 years), LVEF (mean 22.3 and 22.9), and QRS duration (153.4&plusmn;24.7 ms and 151.0&plusmn;23.6). There was no difference in the primary outcome of death or HF hospitalization, but there was a nearly significant trend for fewer HF hospitalizations with CRT-D (HR = 0.58, p = 0.052). The change in six-minute walk duration between baseline and 12 months was similar in the two groups, but the CRT-D group showed a nearly significant trend for greater improvement in Minnesota Living with Heart Failure Score between baseline and six months (p = 0.057). Of note, CRT was suboptimally delivered with only",
"    <span class=\"nowrap\">",
"     1/3",
"    </span>",
"    of patients receiving &gt;95 percent ventricular pacing and only one patient underwent AV node ablation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Role of AV node ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with LV dyssynchrony, benefit from CRT requires BiV pacing to occur most of the time (ie, intrinsic dyssynchronous conduction should be rare). This can be difficult to accomplish in patients with AF if conduction through the AV node is rapid. However, AV node ablation eliminates intrinsic conduction, resulting in ventricular pacing 100 percent of the time.",
"   </p>",
"   <p>",
"    The role of AV node ablation in combination with CRT was evaluated in a series of 673 patients receiving a CRT device for conventional indications (LVEF &le;35 percent, NYHA class &ge;II, and a QRS duration &gt;120 msec) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/17\">",
"     17",
"    </a>",
"    ]. Among the 162 patients in this cohort with chronic AF, 48 were given medical therapy for rate control and 114 underwent AV node ablation. In contrast to the above described studies in which AV node ablation was necessary for rate control, AV node ablation in this study was performed to ensure frequent BiV pacing (&gt;85 percent of the time).",
"   </p>",
"   <p>",
"    At four-year follow up, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with AF and sinus rhythm had similar improvements in LVEF, reverse remodeling, and exercise tolerance.",
"     </li>",
"     <li>",
"      Among patients with AF, the benefits of CRT were only seen in those patients who had undergone AV node ablation. Despite BiV pacing more than 85 percent of the time, patients being treated with medications for rate control showed no improvement in LV function or functional capacity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another observational study suggested that AV node ablation plus CRT may significantly improve survival compared to CRT alone [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/18\">",
"     18",
"    </a>",
"    ]. Among 1285 patients treated with CRT, 243 were in AF. Rate control was achieved by AV node ablation in 188 patients and medical therapy in 55; all patients had at least 85 percent BiV pacing. During 34 months median follow-up, mortality was significantly lower in patients treated with AV node ablation (4.3 versus 15.2 percent in patients treated with drugs for rate control, adjusted hazard ratio 0.26 for all cause mortality and 0.15 for HF mortality).",
"   </p>",
"   <p>",
"    These results suggest that clinicians following CRT recipients should target complete (100 percent) BiV pacing for CRT to achieve maximum benefit. A study reporting on 36,935 patients whose CRT devices were followed in a remote monitoring network found that increased percentages of biventricular pacing were associated with significant mortality reduction. The optimal cut-point was 98.4 percent and patients with a biventricular pacing percentage above 99.6 percent experienced up to a 24 percent reduction in mortality risk compared to patients with lesser percentages of CRT [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/19\">",
"     19",
"    </a>",
"    ]. This observation has not been confirmed by randomized trials. Until such data are available, the indications for BiV pacing in combination with AV junction ablation are uncertain. This modality may be considered particularly in patients with significant left ventricular dysfunction at baseline and those who deteriorate with RV pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/4,20\">",
"     4,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Comparison with pulmonary vein isolation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available comparing CRT with or without AV node ablation to other therapies for AF in patients with HF. A small randomized trial suggested that, in appropriately selected patients with AF and HF, pulmonary vein isolation may produce a greater increase in LVEF and greater improvements in six-minute walk distance and quality of life than CRT with AV node ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"     \"Atrial fibrillation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EFFECT OF CRT ON AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac resynchronization therapy has a favorable impact on potential risk factors for AF such as neurohormonal activation, left ventricular systolic dysfunction, atrial size and degree of mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/10,22-24\">",
"     10,22-24",
"    </a>",
"    ]. However, it is not clear if CRT reduces the incidence of AF. A small observational study found a reduced incidence of AF in CRT-treated patients compared with matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/25\">",
"     25",
"    </a>",
"    ]. However, CRT did not decrease the incidence of AF in large randomized trials, although AF was not a prespecified end point [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/14,26\">",
"     14,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15416960\">",
"    <span class=\"h1\">",
"     OUR APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our recommendations for CRT in patients with AF are generally in agreement with the 2012",
"    <span class=\"nowrap\">",
"     ACC/AHA/HRS",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with AF and a left ventricular ejection fraction (LVEF) &le;35 percent who require ventricular pacing or otherwise meet CRT criteria",
"      <strong>",
"       and",
"      </strong>",
"      in whom AV nodal ablation or pharmacologic rate control will allow near 100 percent ventricular pacing with CRT, we suggest CRT.",
"     </li>",
"     <li>",
"      In the above statement, &ldquo;otherwise meet CRT criteria&rdquo; means LBBB with QRS &ge;120 ms and NYHA class II, III, or ambulatory IV symptoms on optimal medical therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with AF, CRT can be achieved with a VVIR or a DDDR pacing modality, depending upon whether or not the patient has chronic or paroxysmal AF.",
"   </p>",
"   <p>",
"    Most patients who satisfy either of the above criteria are also candidates for an ICD and should receive a combined device (CRT-D). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H14#H14\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Role of an ICD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MAJOR SOCIETY GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major society guidelines have noted that the strength of evidence supporting CRT use in patients in sinus rhythm is greater than that supporting use in patients in atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2012 focused update to the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    guidelines for device-based therapy include the following recommendations that apply to certain patients with AF [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CRT can be useful in patients with AF who have a left ventricular ejection fraction (LVEF) &le;35 percent on guideline-directed medical therapy if a) the patient requires ventricular pacing or otherwise meets CRT criteria and b) AV nodal ablation or pharmacologic rate control will allow near 100 percent ventricular pacing with CRT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &ldquo;Otherwise meets CRT criteria&rdquo; in this context means a QRS duration &ge;0.12 seconds and NYHA functional class III or ambulatory class IV HF symptoms on optimal recommended medical therapy.",
"    <br/>",
"    <br/>",
"    A similar recommendation was included in the 2010 European Society of Cardiology device therapy guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/31\">",
"     31",
"    </a>",
"    ]. A similar recommendation limited to NYHA class III patients was included in the 2010 Heart Failure Society of America guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/983/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CRT can be useful for patients on guideline-directed medical therapy who have an LVEF&le;35 percent and who are undergoing new or replacement implantation of a permanent pacemaker with anticipated requirement for significant (&gt;40 percent) ventricular pacing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/34/37410?source=see_link\">",
"       \"Patient information: Cardiac resynchronization therapy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although cardiac resynchronization therapy improves some potential risk factors for AF such as atrial size and left ventricular systolic function, CRT has NOT been shown to decrease the incidence of new AF.",
"     </li>",
"     <li>",
"      In patients with AF and a left ventricular ejection fraction (LVEF) &le;35 percent who require ventricular pacing or otherwise meet CRT criteria",
"      <strong>",
"       and",
"      </strong>",
"      in whom AV nodal ablation or pharmacologic rate control will allow near 100 percent ventricular pacing with CRT, we suggest CRT (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15416960\">",
"       'Our approach'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In the above statement, &ldquo;otherwise meet CRT criteria&rdquo; means LBBB with QRS &ge;120 ms and NYHA class II, III, or ambulatory IV symptoms on optimal medical therapy.",
"     </li>",
"     <li>",
"      Most patients who satisfy either of the above criteria are also candidates for an ICD and should receive a combined device. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H14#H14\">",
"       \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Role of an ICD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary vein isolation is another potential treatment option in patients with AF and HF. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Comparison with pulmonary vein isolation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H954285\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Leonard I. Ganz for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/1\">",
"      Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003; 91:2D.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/2\">",
"      Vernooy K, Dijkman B, Cheriex EC, et al. Ventricular remodeling during long-term right ventricular pacing following His bundle ablation. Am J Cardiol 2006; 97:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/3\">",
"      Tops LF, Schalij MJ, Holman ER, et al. Right ventricular pacing can induce ventricular dyssynchrony in patients with atrial fibrillation after atrioventricular node ablation. J Am Coll Cardiol 2006; 48:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/4\">",
"      Leon AR, Greenberg JM, Kanuru N, et al. Cardiac resynchronization in patients with congestive heart failure and chronic atrial fibrillation: effect of upgrading to biventricular pacing after chronic right ventricular pacing. J Am Coll Cardiol 2002; 39:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/5\">",
"      Brignole M, Gammage M, Puggioni E, et al. Comparative assessment of right, left, and biventricular pacing in patients with permanent atrial fibrillation. Eur Heart J 2005; 26:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/6\">",
"      Doshi RN, Daoud EG, Fellows C, et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 2005; 16:1160.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/cdrh/pdf3/p030035.html.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/8\">",
"      Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/9\">",
"      Upadhyay GA, Choudhry NK, Auricchio A, et al. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. J Am Coll Cardiol 2008; 52:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/10\">",
"      Leclercq C, Walker S, Linde C, et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 2002; 23:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/11\">",
"      Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002; 40:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/12\">",
"      Khadjooi K, Foley PW, Chalil S, et al. Long-term effects of cardiac resynchronisation therapy in patients with atrial fibrillation. Heart 2008; 94:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/13\">",
"      Delnoy PP, Ottervanger JP, Luttikhuis HO, et al. Comparison of usefulness of cardiac resynchronization therapy in patients with atrial fibrillation and heart failure versus patients with sinus rhythm and heart failure. Am J Cardiol 2007; 99:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/14\">",
"      Hoppe UC, Casares JM, Eiskjaer H, et al. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. Circulation 2006; 114:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/15\">",
"      Wilton SB, Leung AA, Ghali WA, et al. Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm 2011; 8:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/16\">",
"      Healey JS, Hohnloser SH, Exner DV, et al. Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail 2012; 5:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/17\">",
"      Gasparini M, Auricchio A, Regoli F, et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol 2006; 48:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/18\">",
"      Gasparini M, Auricchio A, Metra M, et al. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J 2008; 29:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/19\">",
"      Hayes DL, Boehmer JP, Day JD, et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm 2011; 8:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/20\">",
"      Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002; 288:3115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/21\">",
"      Khan MN, Ja&iuml;s P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008; 359:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/22\">",
"      Saxon LA, De Marco T, Schafer J, et al. Effects of long-term biventricular stimulation for resynchronization on echocardiographic measures of remodeling. Circulation 2002; 105:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/23\">",
"      St John Sutton MG, Plappert T, Abraham WT, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 2003; 107:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/24\">",
"      Higgins SL, Hummel JD, Niazi IK, et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 2003; 42:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/25\">",
"      Fung JW, Yu CM, Chan JY, et al. Effects of cardiac resynchronization therapy on incidence of atrial fibrillation in patients with poor left ventricular systolic function. Am J Cardiol 2005; 96:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/26\">",
"      Saxon LA. Does cardiac resynchronization therapy reduce the incidence of atrial fibrillation, and does atrial fibrillation compromise the cardiac resynchronization therapy effect? Heart Rhythm 2007; 4:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/27\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/28\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/29\">",
"      . Electrophysiologic testing and the use of devices in heart failure. J Card Fail 2006; 12:e70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/30\">",
"      Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. [corrected]. Circulation 2012; 126:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/31\">",
"      Dickstein K, Vardas PE, Auricchio A, et al. 2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur J Heart Fail 2010; 12:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/983/abstract/32\">",
"      . HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 2006; 12:e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3515 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-9685F97C73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_61_983=[""].join("\n");
var outline_f0_61_983=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      USE OF CRT IN AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Patients with an indication for AV node ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Role of AV node ablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Comparison with pulmonary vein isolation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EFFECT OF CRT ON AF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15416960\">",
"      OUR APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MAJOR SOCIETY GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H954285\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3515\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3515|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31510?source=related_link\">",
"      Overview of cardiac pacing in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/34/37410?source=related_link\">",
"      Patient information: Cardiac resynchronization therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10823?source=related_link\">",
"      Rationale for and mechanisms of benefit of cardiac resynchronization therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_61_984="Liquid ventilation";
var content_f0_61_984=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Liquid ventilation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/61/984/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/61/984/contributors\">",
"     Karen J Tietze, PharmD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/61/984/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/61/984/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/61/984/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/61/984/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/61/984/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/61/984/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liquid ventilation (LV) is a technique of mechanical ventilation in which the lungs are insufflated with an oxygenated perfluorochemical liquid rather than an oxygen-containing gas mixture. The use of perfluorochemicals, rather than nitrogen, as the inert carrier of oxygen and carbon dioxide offers a number of theoretical advantages for the treatment of acute lung injury, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reducing surface tension by maintaining a fluid interface with alveoli",
"     </li>",
"     <li>",
"      Opening of collapsed alveoli by hydraulic pressure with a lower risk of barotrauma",
"     </li>",
"     <li>",
"      Providing a reservoir in which oxygen and carbon dioxide can be exchanged with pulmonary capillary blood",
"     </li>",
"     <li>",
"      Functioning as a high efficiency heat exchanger",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite its theoretical advantages, efficacy studies have been disappointing and the optimal clinical use of LV has yet to be defined [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The technique and potential applications of LV will be reviewed here. Conventional and alternative modes of gas-phase mechanical ventilation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=see_link\">",
"     \"Overview of mechanical ventilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link\">",
"     \"Modes of mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROPERTIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal fluid for liquid ventilation is nontoxic, has a low surface tension, is capable of dissolving large amounts of oxygen and carbon dioxide, has minimal systemic absorption, and is chemically stable [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/2\">",
"     2",
"    </a>",
"    ]. Following work with hyperbaric saline ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/3\">",
"     3",
"    </a>",
"    ], researchers demonstrated that perfluorochemicals (PFCs) had many of these properties and could be used as a medium for liquid breathing in rodents [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Physical properties",
"    </span>",
"    &nbsp;&mdash;&nbsp;PFCs are organic compounds in which some carbon-bound hydrogen atoms have been replaced with fluorine atoms [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/5\">",
"     5",
"    </a>",
"    ]. Perflubron (LiquiVent",
"    <sup>",
"     &reg;",
"    </sup>",
"    ), the only medical grade PFC available for use in human LV trials, consists of a long, linear-fluorinated hydrocarbon chain. Perflubron contains one bromide atom, making it radiopaque [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hundreds of different PFC fluids with unique biomedical properties exist. The structure of several examples of these compounds is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef80558 \" href=\"UTD.htm?6/20/6477\">",
"     figure 1",
"    </a>",
"    ). The table compares the physical properties of air, water, and saline with three PFCs that have been studied for liquid ventilation (",
"    <a class=\"graphic graphic_table graphicRef52864 \" href=\"UTD.htm?15/1/15388\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PFC fluids are clear, colorless, odorless, and inert. Oxygen, carbon dioxide, and other gases are highly soluble in these fluids; they can dissolve over 15 times the amount of oxygen per given volume as plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/8\">",
"     8",
"    </a>",
"    ]. PFCs are poor solvents for most other biological compounds.",
"   </p>",
"   <p>",
"    PFCs are stable, insoluble in water, can be stored indefinitely at room temperature, and can be autoclaved [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In contrast to saline, PFCs do not wash out surfactant [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/1\">",
"     1",
"    </a>",
"    ]. Almost all PFC fluids have low surface tension and are nonbiotransformable. However, PFCs have a high viscosity, which makes their flow characteristics problematic under certain circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very small amounts of PFCs diffuse into the pulmonary capillary blood and dissolve in blood lipids [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/10\">",
"     10",
"    </a>",
"    ]. The rate of uptake in the blood depends upon the PFC vapor pressure, permeability coefficients of the blood vessels, solubility of the particular PFC used, and the degree of",
"    <span class=\"nowrap\">",
"     ventilation/perfusion",
"    </span>",
"    matching.",
"   </p>",
"   <p>",
"    Absorbed PFCs are scavenged by macrophages. The main route of PFC elimination is through the lungs via volatilization [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. To a smaller degree, the chemicals are eliminated through the skin by transpiration. Perflubron blood concentrations are low but measurable, and persist for at least eight days following administration of the last dose of perflubron [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perflubron may persist in extrapulmonary tissues for years following LV. Two case reports note the continued presence of perflubron in the mediastinum, the retroperitoneum, and the pleural space for nine and twelve years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two methods of PFC-based liquid ventilation have been used: total (tidal) liquid ventilation and partial liquid ventilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Total liquid ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In total liquid ventilation (TLV), the entire lung is filled with an oxygenated PFC liquid, and a liquid tidal volume of PFC is actively pumped into and out of the lungs. A specialized apparatus is required to deliver and remove the relatively dense, viscous PFC tidal volumes, and to extracorporeally oxygenate and remove carbon dioxide from the liquid [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/2,9,16\">",
"     2,9,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TLV is initiated by insufflating the desired volume of pre-oxygenated PFC liquid (functional residual capacity plus tidal volume) into the lungs using a gravity-assisted device or more specialized equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. Optimum ventilation and oxygenation depend upon adequate minute ventilation coupled with sufficient time for diffusion of respiratory gases to and from the PFC liquid [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. During the maintenance phase of TLV, a low respiratory rate (eg, 4 to 6 breaths per minute) is set with an inspiratory-to-expiratory (I:E) ratio of 1:2 to 1:3 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/17\">",
"     17",
"    </a>",
"    ]. At these respiratory rates and timing ratios, PFC fluid dwells in the lung long enough for diffusion of respiratory gases to occur, thus effecting pulmonary gas exchange. Tidal volumes and peak inspiratory and positive end expiratory pressures (PEEP) are adjusted based upon pulmonary mechanics and blood gases in the same manner as when gas ventilation is employed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=see_link\">",
"     \"Positive end-expiratory pressure (PEEP)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TLV is weaned when sufficient clinical improvement has occurred such that gas ventilation will be adequate to support the patient; specific weaning parameters and techniques have not been fully evaluated. The return to gas ventilation is accomplished by a transition through a period of partial liquid ventilation (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Partial liquid ventilation'",
"    </a>",
"    below). PFC liquid is removed at the end of the expiratory phase, leaving a volume of PFC fluid equivalent to the functional residual capacity of the lung. Gas ventilation is begun, and the PFC fluid is not replaced or augmented as it is evaporated; elimination from the lung by evaporation generally requires one to seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/6,18\">",
"     6,18",
"    </a>",
"    ]. In some cases, small amounts of PFC are radiographically apparent in the lungs for several weeks or longer without apparent ill effects [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Partial liquid ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In partial liquid ventilation (PLV), the lungs are slowly filled with a volume of PFC equivalent or close to the FRC during gas ventilation. The PFC within the lungs is oxygenated and carbon dioxide is removed by means of gas breaths cycling in the lungs by a conventional gas ventilator [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PLV is initiated by insufflating PFC liquid (approximately 20 to 30",
"    <span class=\"nowrap\">",
"     mL/kg)",
"    </span>",
"    into the lungs using an intravenous syringe pump or by slowly pushing the fluid in over a 15-minute to one-hour period. The functional residual capacity is reached when a meniscus of PFC is present within the endotracheal tube at end-expiration [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As the fluid evaporates out of the lungs, it is intermittently and gradually replaced with additional PFC at approximately 2 to 8",
"    <span class=\"nowrap\">",
"     mL/kg/hr",
"    </span>",
"    to maintain a total liquid volume of functional residual capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. Typically, but not exclusively, pressure-controlled ventilation with the addition of PEEP is used to deliver gas ventilation, and FIO",
"    <sub>",
"     2",
"    </sub>",
"    and PEEP are adjusted based upon pulmonary mechanics and blood gases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Airway suctioning is still required with PLV [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/1\">",
"     1",
"    </a>",
"    ]. PLV is discontinued by ceasing to replace the PFC that is lost through evaporation. Most of the intrapulmonary PFC evaporates in the next one to seven days, allowing a transition to gas ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Comparison",
"    </span>",
"    &nbsp;&mdash;&nbsp;TLV allows the lavage and removal of lung secretions, meconium, or alveolar edema from the lower airways to a greater extent than PLV. In addition, the distribution of PFC within the lungs may be more uniform during TLV than PLV. However, TLV requires a specialized delivery apparatus, and increased airway resistance can make the tidal delivery of viscous PFCs difficult.",
"   </p>",
"   <p>",
"    PLV provides some of the same benefits as TLV by maintaining a liquid interface in the alveoli, but does not require specialized equipment. The technique may also be possible in some patients in whom elevated airway resistance precludes the use of TLV. Periodic repositioning of the patient is required with both modes to ensure optimal distribution of PFC fluid within the lungs, but is more important in PLV to maintain a liquid interface in as many alveoli as possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;LV offers a number of theoretical advantages over conventional gas ventilation, including better gas exchange and functional lung recovery by any of several mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alveolar recruitment &ndash; Filling of alveoli with liquid rather than gas eliminates air-liquid interfaces and greatly reduces surface tension forces. Collapsed alveoli may also be recruited and stabilized by the hydraulic forces provided during LV. Alveolar expansion and stability is thus facilitated at much lower airway pressures, reducing the risk of barotrauma [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/16,21\">",
"       16,21",
"      </a>",
"      ]. As more alveoli are filled with oxygen-rich PFC, the effective diffusing surface of the lung increases and is reflected by improvement in arterial oxygenation and compliance [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Better",
"      <span class=\"nowrap\">",
"       V/Q",
"      </span>",
"      matching &ndash; PFC fluids are denser than water and therefore deposit in dependent regions of the lungs. They improve",
"      <span class=\"nowrap\">",
"       ventilation/perfusion",
"      </span>",
"      matching by facilitating gas exchange in lung units that were previously perfused but unventilated. The weight of PFCs within dependent lung zones also may redistribute pulmonary blood flow to nondependent zones that were previously ventilated but unperfused [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lavage &ndash; LV facilitates the removal of exudative material from the lung but does not interfere substantially with the production or function of surfactant [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/1,25\">",
"       1,25",
"      </a>",
"      ]. During TLV, the cyclical removal and replacement of PFC liquid may cleanse the lungs while maintaining gas exchange [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/26\">",
"       26",
"      </a>",
"      ]. During PLV, exudative material in the peripheral airways and alveoli is lavaged to the central airways for removal via suctioning [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antiinflammatory effects &ndash; Some studies suggest reduced neutrophil and alveolar macrophage responses exist in the presence of PFCs, including attenuation of neutrophil adhesion, activation, and migration [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/27-33\">",
"       27-33",
"      </a>",
"      ]. The removal of inflammatory cells and their mediators from the alveolar spaces may also provide benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/28,34\">",
"       28,34",
"      </a>",
"      ]. Finally, filling of the alveolus with PFCs may provide a mechanical barrier to intraalveolar exudation and leukocyte",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      red blood cell translocation, with potential beneficial effects in reducing the intensity of inflammation and secondary lung injury.",
"     </li>",
"     <li>",
"      Temperature regulation &ndash; PFC liquids have a higher heat capacity than conventional gas mixtures. This allows the lung and pulmonary circulation to act as an internal heat exchanger [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/35\">",
"       35",
"      </a>",
"      ]. PFC liquids can be used to warm the lungs and increase core body temperature or cool the lungs and decrease core body temperature, as required by clinical circumstances [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/6,36\">",
"       6,36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     POTENTIAL INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The unique properties of PFC-based LV make the technique potentially useful in a variety of situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neonatal applications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns can suffer from a variety of lung diseases that may respond favorably to LV.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory distress syndrome &ndash; Exogenous surfactant therapy in infants with neonatal respiratory distress syndrome (hyaline membrane disease) is limited by unequal delivery and distribution within the injured or premature lung [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/37\">",
"       37",
"      </a>",
"      ]. LV may facilitate more uniform endogenous surfactant distribution, and may be of use in surfactant-unresponsive cases. In either event, LV can reduce surface tension, thereby reducing inflation pressure and barotrauma, and may stimulate surfactant synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/25,38\">",
"       25,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Meconium aspiration &ndash; Lavage associated with TLV and PLV may remove meconium from the airways more effectively than conventional measures [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/39-41\">",
"       39-41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Persistent pulmonary hypertension of the newborn &ndash; LV provides uniform delivery of oxygen to the distal regions of the lungs, potentially improving",
"      <span class=\"nowrap\">",
"       ventilation/perfusion",
"      </span>",
"      matching and facilitating pulmonary vasodilation [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Congenital diaphragmatic hernia &ndash; PLV may improve gas exchange more effectively than conventional gas ventilation in newborns with severe congenital diaphragmatic hernia and may provide mechanical stimuli that favor neonatal lung growth [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/42-45\">",
"       42-45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Temperature control &ndash; The heat exchange characteristic of PFCs may help maintain normothermia in premature infants with less reliance upon radiant warmers, which increase insensible water loss [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lung protection during cardiopulmonary bypass &ndash; Full, functional residual capacity dosing prior to bypass may reduce cardiopulmonary bypass-associated lung injury [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/46\">",
"       46",
"      </a>",
"      ]. Anti-inflammatory effects, alveolar distention, oxygen-carrying capacity, and surfactant-like properties may protect the lung before and during cardiopulmonary bypass.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Adult applications",
"    </span>",
"    &nbsp;&mdash;&nbsp;LV appears most suited for use in adults with the acute respiratory distress syndrome (ARDS), and may also be useful in several other circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute respiratory distress syndrome &ndash; LV potentially can improve gas exchange in the acute respiratory distress syndrome (ARDS) by virtue of recruiting the atelectatic, consolidated, dependent regions of the lungs that contribute to the physiologic shunt observed during gas ventilation. Pulmonary blood flow is also redistributed to less severely injured",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      atelectatic regions of the lungs, thus improving",
"      <span class=\"nowrap\">",
"       ventilation/perfusion",
"      </span>",
"      matching [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/16,23,24,47\">",
"       16,23,24,47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pneumonia &ndash; Lavage associated with TLV and PLV removes infectious and inflammatory debris from the airways [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. Antibiotics such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      can be suspended within the PFC vehicle to potentially facilitate treatment or prevention of pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cancer therapy &ndash; LV may augment the antineoplastic effects of radiotherapy and chemotherapy in the lung by inducing localized hyperthermia or hyperoxia of the lung surface. Concentrated, topical chemotherapeutic agents can also be delivered [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/5,8,49\">",
"       5,8,49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Drug delivery &ndash; Mechanical abnormalities of the lung, intrapulmonary shunting,",
"      <span class=\"nowrap\">",
"       ventilation/perfusion",
"      </span>",
"      mismatching, and elevated surface tension impede effective delivery of systemic and intratracheal drugs to the lungs during conventional gas ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/50\">",
"       50",
"      </a>",
"      ]. Data from preliminary animal studies suggest that pulmonary uptake of antibiotics and the efficacy of vasoactive drugs are better following intratracheal administration during LV than when administered intravenously [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/50-52\">",
"       50-52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Donor lung preservation &ndash; Because perfluorochemicals have both direct antiinflammatory and alveolar stabilizing effects, these agents have been proposed as potential useful tools for organ preservation prior to lung transplantation. Preliminary investigations have suggested that LV results in decreased alveolar destruction when compared to standard (gas) ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5640?source=see_link\">",
"       \"Lung transplantation: Donor lung preservation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18566?source=see_link\">",
"       \"Management of the potential deceased donor\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies over the last three decades have evaluated the ability of liquid ventilation to improve gas exchange and pulmonary function in animal models. Far fewer investigations have been performed in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/18,39,40,42,55-63\">",
"     18,39,40,42,55-63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two trials have compared partial liquid ventilation (PLV) versus conventional mechanical ventilation (CMV) in adults with acute respiratory distress syndrome (ARDS):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the larger trial, 311 patients were randomly assigned to receive CMV, low dose PLV (lungs filled to the carina in the supine position), or high dose PLV (lungs filled to 5 cm caudal to the incisors in the supine position) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/63\">",
"       63",
"      </a>",
"      ]. There was no difference in mortality among the groups; however, patients who received PLV had fewer ventilator-free days and more adverse events including pneumothoraces, hypoxic episodes, and hypotensive episodes.",
"     </li>",
"     <li>",
"      In a trial of 90 patients, those who received PLV were less likely to have progressive deterioration of gas exchange; however, there was no difference in the number of ventilator-free days, the incidence of mortality, or any respiratory parameter [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a small trial that included 13 neonates with congenital diaphragmatic hernias on extracorporeal life support (ECLS), patients who received PLV had a nonstatistically significant improvement in survival and time on ECLS compared to patients who received CMV [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/62\">",
"     62",
"    </a>",
"    ]. However, ventilator-free days were greater in the CMV group.",
"   </p>",
"   <p>",
"    Based on these studies, routine use of PLV cannot be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complete range of toxicity due to PFCs is not known. Early studies using TLV reported an increase in pulmonary vascular resistance with a decrease in cardiac index of approximately 40 percent, which resulted in lactic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/1\">",
"     1",
"    </a>",
"    ]. This probably was a consequence of lung overexpansion, which may decrease cardiac output and arterial blood pressure. In contrast, adverse direct hemodynamic effects appear uncommon during PLV.",
"   </p>",
"   <p>",
"    Other adverse effects observed during PFC LV include mucous plug formation, pneumothoraces, and bleeding complications, but it is unclear to what degree these relate to LV rather than the underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Morphologic, biochemical, and pathologic examination of numerous mature and immature species has revealed no adverse effects of PFCs [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/8\">",
"     8",
"    </a>",
"    ]. The long-term adverse effects of breathing PFCs appear to be negligible but remain under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LV potentially can complicate some of the supportive and general care that ventilated patients receive in the intensive care unit:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PFC fluid is almost twice as dense as saline, and patient weights should not be followed as the sole index of fluid balance when LV is used [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. A dry weight should be obtained before the start of LV, and patients should be weighed again immediately after the lungs are filled with PFC fluid.",
"     </li>",
"     <li>",
"      PFCs are radiopaque and will eliminate much of the diagnostic utility of chest radiography. All lung tissue will appear opacified during TLV; during PLV, an anterior-posterior supine film may appear uniformly radiopaque, but a lateral view of the chest will reveal the distribution of PFC primarily within the dependent portions of the lung. A chest radiograph should be obtained prior to and within an hour of filling the lung with PFC fluid.",
"     </li>",
"     <li>",
"      Heart sounds are more distinct during TLV than PLV. Breath sounds during PLV are notable for the presence of fine rales and coarse rhonchi. No audible breath sounds are present during TLV.",
"     </li>",
"     <li>",
"      The impact of LV upon the development of nosocomial pneumonia is uncertain. Lavaging the lung of infectious exudate during LV may be beneficial, but this may be offset by the loss of diagnostic information usually provided by chest radiography [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/6,26,39\">",
"       6,26,39",
"      </a>",
"      ]. PFCs are thought to be inert.",
"     </li>",
"     <li>",
"      Use of liquid ventilation is unpleasant for the patient, and therefore deep sedation and paralysis are necessary [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/6,16\">",
"       6,16",
"      </a>",
"      ]. The principles of using sedative and paralytic agents are similar to those applied when conventional gas ventilation is employed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=see_link\">",
"       \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=see_link\">",
"       \"Use of neuromuscular blocking medications in critically ill patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     FUTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive doses of perflubron may explain the negative results of early human trials [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/64\">",
"     64",
"    </a>",
"    ]. This is supported by an animal study, in which rats given a low dose (7",
"    <span class=\"nowrap\">",
"     mL/kg)",
"    </span>",
"    of perflubron had less microvascular lung injury than rats given a near functional residual capacity dose (20",
"    <span class=\"nowrap\">",
"     mL/kg)",
"    </span>",
"    of perflubron [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/984/abstract/65\">",
"     65",
"    </a>",
"    ]. Future efforts may involve studying the effects of various doses of perflubron.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liquid ventilation (LV) is a technique of mechanical ventilation in which the lungs are insufflated with oxygenated perfluorochemical (PFC) liquid rather than gas. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PFC liquids are stable and nontoxic, with minimal systemic absorption. They dissolve large amounts of oxygen and carbon dioxide; thus, they are ideal for gas exchange. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Properties'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two techniques of PFC-based liquid ventilation have been used, total (tidal) liquid ventilation and partial liquid ventilation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Theoretical advantages of LV over conventional gas ventilation include recruitment and stabilization of alveoli, improvement in",
"      <span class=\"nowrap\">",
"       V/Q",
"      </span>",
"      matching, removal of exudative material from the lung, direct anti-inflammatory effects, and temperature regulation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Physiologic outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In theory, LV may be of benefit for numerous neonatal and adult diseases. Clinical trials, however, have shown little improvement in important clinical outcomes. As a result, LV cannot be recommended in routine clinical care. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Potential indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse effects observed during LV include mucous plug formation, pneumothoraces, and bleeding complications, although it is unclear whether these were due to LV or the underlying disease. LV can complicate the supportive and general care of patients. For example, patient weight cannot be followed as an index of fluid balance and deep sedation and paralysis is required. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Adverse Effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/1\">",
"      Degraeuwe PL, Vos GD, Blanco CE. Perfluorochemical liquid ventilation: from the animal laboratory to the intensive care unit. Int J Artif Organs 1995; 18:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/2\">",
"      Norris MK, Fuhrman BP, Leach CL. Liquid ventilation: it's not science fiction anymore. AACN Clin Issues Crit Care Nurs 1994; 5:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/3\">",
"      KYLSTRA JA, TISSING MO. Of mice as fish. Trans Am Soc Artif Intern Organs 1962; 8:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/4\">",
"      Clark LC Jr, Gollan F. Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science 1966; 152:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/5\">",
"      Riess JG. Overview of progress in the fluorocarbon approach to in vivo oxygen delivery. Biomater Artif Cells Immobilization Biotechnol 1992; 20:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/6\">",
"      Cox CA, Wolfson MR, Shaffer TH. Liquid ventilation: a comprehensive overview. Neonatal Netw 1996; 15:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/7\">",
"      Shaffer TH. A brief review: liquid ventilation. Undersea Biomed Res 1987; 14:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/8\">",
"      Shaffer TH, Wolfson MR, Clark LC Jr. Liquid ventilation. Pediatr Pulmonol 1992; 14:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/9\">",
"      Greenspan JS. Physiology and clinical role of liquid ventilation therapy. J Perinatol 1996; 16:S47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/10\">",
"      Wolfson, MR, Kechner, NE, Rubenstein, D, et al. Perfluorochemical (PFC) uptake and biodistribution following liquid assisted ventilation in the immature lamb. Pediatr Res 1994; 35:A246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/11\">",
"      Gauthier SP, Wolfson MR, Deoras KS, Shaffer TH. Structure-function of airway generations 0 to 4 in the preterm lamb. Pediatr Res 1992; 31:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/12\">",
"      Wolfson, MR, Clark, LC, Hoffmann, RE, et al. Liquid ventilation of neonates: Uptake, distribution, and elimination of the liquid. Pediatr Res 1990; 27:37A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/13\">",
"      Reickert C, Pranikoff T, Overbeck M, et al. The pulmonary and systemic distribution and elimination of perflubron from adult patients treated with partial liquid ventilation. Chest 2001; 119:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/14\">",
"      Hagerty RD, Phelan MP, Morrison SC, Hatem SF. Radiographic detection of perflubron fluoromediastinum and fluororetroperitoneum 9 years after partial liquid ventilation. Emerg Radiol 2008; 15:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/15\">",
"      Servaes S, Epelman M. Perflubron residua: 12 years following therapy. Pediatr Radiol 2009; 39:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/16\">",
"      Dirkes S. Liquid ventilation: new frontiers in the treatment of ARDS. Crit Care Nurse 1996; 16:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/17\">",
"      Koen PA, Wolfson MR, Shaffer TH. Fluorocarbon ventilation: maximal expiratory flows and CO2 elimination. Pediatr Res 1988; 24:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/18\">",
"      Leach CL, Greenspan JS, Rubenstein SD, et al. Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. The LiquiVent Study Group. N Engl J Med 1996; 335:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/19\">",
"      Hirschl RB. Advances in the management of respiratory failure. Liquid ventilation in the setting of respiratory failure. ASAIO J 1996; 42:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/20\">",
"      Kirmse M, Fujino Y, Hess D, Kacmarek RM. Positive end-expiratory pressure improves gas exchange and pulmonary mechanics during partial liquid ventilation. Am J Respir Crit Care Med 1998; 158:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/21\">",
"      T&uuml;t&uuml;nc&uuml; AS, Faithfull NS, Lachmann B. Intratracheal perfluorocarbon administration combined with mechanical ventilation in experimental respiratory distress syndrome: dose-dependent improvement of gas exchange. Crit Care Med 1993; 21:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/22\">",
"      Fuhrman BP, Paczan PR, DeFrancisis M. Perfluorocarbon-associated gas exchange. Crit Care Med 1991; 19:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/23\">",
"      Berry D, Ikegami M, Jobe A. Respiratory distress and surfactant inhibition following vagotomy in rabbits. J Appl Physiol 1986; 61:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/24\">",
"      Lowe CA, Shaffer TH. Pulmonary vascular resistance in the fluorocarbon-filled lung. J Appl Physiol 1986; 60:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/25\">",
"      Steinhorn DM, Leach CL, Fuhrman BP, Holm BA. Partial liquid ventilation enhances surfactant phospholipid production. Crit Care Med 1996; 24:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/26\">",
"      Richman PS, Wolfson MR, Shaffer TH. Lung lavage with oxygenated perfluorochemical liquid in acute lung injury. Crit Care Med 1993; 21:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/27\">",
"      Angelova M, Nakazawa K, Yokoyama K, Makita K. Effects of partial liquid ventilation on lipopolysaccharide-induced inflammatory responses in rats. Resuscitation 2004; 62:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/28\">",
"      Smith TM, Steinhorn DM, Thusu K, et al. A liquid perfluorochemical decreases the in vitro production of reactive oxygen species by alveolar macrophages. Crit Care Med 1995; 23:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/29\">",
"      Virmani R, Fink LM, Gunter K, English D. Effect of perfluorochemical blood substitutes on human neutrophil function. Transfusion 1984; 24:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/30\">",
"      Varani J, Hirschl RB, Dame M, Johnson K. Perfluorocarbon protects lung epithelial cells from neutrophil-mediated injury in an in vitro model of liquid ventilation therapy. Shock 1996; 6:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/31\">",
"      Koch T, Ragaller M, Haufe D, et al. Perfluorohexane attenuates proinflammatory and procoagulatory response of activated monocytes and alveolar macrophages. Anesthesiology 2001; 94:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/32\">",
"      Nakstad B, Wolfson MR, Shaffer TH, et al. Perfluorochemical liquids modulate cell-mediated inflammatory responses. Crit Care Med 2001; 29:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/33\">",
"      Woods CM, Neslund G, Kornbrust E, Flaim SF. Perflubron attenuates neutrophil adhesion to activated endothelial cells in vitro. Am J Physiol Lung Cell Mol Physiol 2000; 278:L1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/34\">",
"      Kelly KP. Partial liquid ventilation--turning back a PAGE on evolution. Br J Anaesth 1997; 78:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/35\">",
"      Shaffer TH, Forman DL, Wolfson MR. Physiological effects of ventilation with liquid fluorocarbon at controlled temperatures. Undersea Biomed Res 1984; 11:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/36\">",
"      Forman DL, Bhutani VK, Tran N, Shaffer TH. A new approach to induced hypothermia. J Surg Res 1986; 40:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/37\">",
"      Antunes MJ, Greenspan JS, Zukowsky K. Advanced ventilation in the neonate. Nurs Clin North Am 1996; 31:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/38\">",
"      Leach, CL, Holm, BA, Morin, FC, et al. Partial liquid ventilation with LiquiVent' increases endogenous surfactant production in premature lambs with respiratory distress syndrome (RDS). Pediatr Res 1994; 35:220A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/39\">",
"      Hirschl RB, Pranikoff T, Wise C, et al. Initial experience with partial liquid ventilation in adult patients with the acute respiratory distress syndrome. JAMA 1996; 275:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/40\">",
"      Hirschl RB, Pranikoff T, Gauger P, et al. Liquid ventilation in adults, children, and full-term neonates. Lancet 1995; 346:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/41\">",
"      Shaffer TH, Lowe CA, Bhutani VK, Douglas PR. Liquid ventilation: effects on pulmonary function in distressed meconium-stained lambs. Pediatr Res 1984; 18:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/42\">",
"      Pranikoff T, Gauger PG, Hirschl RB. Partial liquid ventilation in newborn patients with congenital diaphragmatic hernia. J Pediatr Surg 1996; 31:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/43\">",
"      Wilcox DT, Glick PL, Karamanoukian HL, et al. Partial liquid ventilation and nitric oxide in congenital diaphragmatic hernia. J Pediatr Surg 1997; 32:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/44\">",
"      Major D, Cadenas M, Cloutier R, et al. Combined gas ventilation and perfluorochemical tracheal instillation as an alternative treatment for lethal congenital diaphragmatic hernia in lambs. J Pediatr Surg 1995; 30:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/45\">",
"      Wilcox DT, Glick PL, Karamanoukian HL, et al. Perfluorocarbon-associated gas exchange improves pulmonary mechanics, oxygenation, ventilation, and allows nitric oxide delivery in the hypoplastic lung congenital diaphragmatic hernia lamb model. Crit Care Med 1995; 23:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/46\">",
"      Cannon ML, Cheifetz IM, Craig DM, et al. Optimizing liquid ventilation as a lung protection strategy for neonatal cardiopulmonary bypass: full functional residual capacity dosing is more effective than half functional residual capacity dosing. Crit Care Med 1999; 27:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/47\">",
"      Hirschl RB, Parent A, Tooley R, et al. Liquid ventilation improves pulmonary function, gas exchange, and lung injury in a model of respiratory failure. Ann Surg 1995; 221:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/48\">",
"      Cullen AB, Cox CA, Hipp SJ, et al. Intra-tracheal delivery strategy of gentamicin with partial liquid ventilation. Respir Med 1999; 93:770.",
"     </a>",
"    </li>",
"    <li>",
"     Sekins KM, Deilman GW, Shaffer TH, et al. Acoustic and physical properties of PFC liquids pertinent to ultrasound lung hyperthermia. 10th Annual North American Hyperthermia Group. Radiation Res Soc. April, 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/50\">",
"      Wolfson MR, Greenspan JS, Shaffer TH. Pulmonary administration of vasoactive substances by perfluorochemical ventilation. Pediatrics 1996; 97:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/51\">",
"      Dickson, EW, Heard, SO, Otto, S, et al. Efficacy of a novel perfluorocarbon-based intrapulmonary drug delivery system. Crit Care Med 1998; 26:143A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/52\">",
"      Franz AR, R&ouml;hlke W, Franke RP, et al. Pulmonary administration of perfluorodecaline- gentamicin and perfluorodecaline- vancomycin emulsions. Am J Respir Crit Care Med 2001; 164:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/53\">",
"      Yoshida S, Sekine Y, Shinozuka N, et al. The efficacy of partial liquid ventilation in lung protection during hypotension and cardiac arrest: preliminary study of lung transplantation using non-heart-beating donors. J Heart Lung Transplant 2005; 24:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/54\">",
"      Loehe F, Mueller C, Bittmann I, et al. Influence of long-term preservation with endobronchially administered perfluorodecalin on pulmonary graft function. Transplantation 2000; 70:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/55\">",
"      Greenspan JS, Wolfson MR, Rubenstein SD, Shaffer TH. Liquid ventilation of human preterm neonates. J Pediatr 1990; 117:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/56\">",
"      Hirschl RB, Conrad S, Kaiser R, et al. Partial liquid ventilation in adult patients with ARDS: a multicenter phase I-II trial. Adult PLV Study Group. Ann Surg 1998; 228:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/57\">",
"      Gauger PG, Pranikoff T, Schreiner RJ, et al. Initial experience with partial liquid ventilation in pediatric patients with the acute respiratory distress syndrome. Crit Care Med 1996; 24:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/58\">",
"      Greenspan JS, Fox WW, Rubenstein SD, et al. Partial liquid ventilation in critically ill infants receiving extracorporeal life support. Philadelphia Liquid Ventilation Consortium. Pediatrics 1997; 99:E2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/59\">",
"      Croce MA, Fabian TC, Patton JH Jr, et al. Partial liquid ventilation decreases the inflammatory response in the alveolar environment of trauma patients. J Trauma 1998; 45:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/60\">",
"      Davies MW, Sargent PH. Partial liquid ventilation for the prevention of mortality and morbidity in paediatric acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev 2004; :CD003845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/61\">",
"      Hirschl RB, Croce M, Gore D, et al. Prospective, randomized, controlled pilot study of partial liquid ventilation in adult acute respiratory distress syndrome. Am J Respir Crit Care Med 2002; 165:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/62\">",
"      Hirschl RB, Philip WF, Glick L, et al. A prospective, randomized pilot trial of perfluorocarbon-induced lung growth in newborns with congenital diaphragmatic hernia. J Pediatr Surg 2003; 38:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/63\">",
"      Kacmarek RM, Wiedemann HP, Lavin PT, et al. Partial liquid ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2006; 173:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/64\">",
"      Lemaire F. Low-dose perfluorocarbon: a revival for partial liquid ventilation? Crit Care Med 2007; 35:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/984/abstract/65\">",
"      Ricard JD, Iserin F, Dreyfuss D, Saumon G. Perflubron dosing affects ventilator-induced lung injury in rats with previous lung injury. Crit Care Med 2007; 35:561.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1608 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-906C751B57-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_61_984=[""].join("\n");
var outline_f0_61_984=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROPERTIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Physical properties",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Total liquid ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Partial liquid ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Comparison",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PHYSIOLOGIC OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      POTENTIAL INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neonatal applications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adult applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      FUTURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1608\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1608|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/20/6477\" title=\"figure 1\">",
"      Perfluorochemical structures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1608|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/1/15388\" title=\"table 1\">",
"      Comparison of PFC properties",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5640?source=related_link\">",
"      Lung transplantation: Donor lung preservation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18566?source=related_link\">",
"      Management of the potential deceased donor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=related_link\">",
"      Modes of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=related_link\">",
"      Positive end-expiratory pressure (PEEP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=related_link\">",
"      Use of neuromuscular blocking medications in critically ill patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_61_985="Influenza virus vaccine (inactivated): Drug information";
var content_f0_61_985=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Influenza virus vaccine (inactivated): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/53/16209?source=see_link\">",
"    see \"Influenza virus vaccine (inactivated): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/21/20824?source=see_link\">",
"    see \"Influenza virus vaccine (inactivated): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14959458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Cell Culture-Derived Seasonal Influenza Vaccine (Flucelvax&reg;)",
"     </span>",
"     <span class=\"collapsible-date\">",
"      December 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Flucelvax&reg; (trivalent influenza virus vaccine) has been approved by the Food and Drug Administration (FDA) to provide active immunity to influenza virus. Flucelvax&reg; is the only inactivated influenza vaccine manufactured using cell culture technology and provides an alternative to influenza vaccines cultured with chicken egg protein. Availability is currently limited, but full distribution is expected during the 2012-2013 influenza season.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, refer to",
"       <a href=\"file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm328982.htm\" target=\"_blank\">",
"        file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm328982.htm",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Distribution of Agriflu&trade; and Fluad&trade; in Canada: Update",
"     </span>",
"     <span class=\"collapsible-date\">",
"      October 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       After completing its safety information review, Health Canada has announced it is releasing two seasonal flu vaccines (Agriflu&trade; and Fluad&trade;) for immediate use in Canada. Recently, Health Canada announced that Novartis Canada had agreed to voluntarily suspend distribution of two seasonal flu vaccines (Agriflu&trade; and Fluad&trade;) in Canada. Several European countries recently suspended use of the vaccines pending examination of white floating material found clumping in the vaccines. This type of clumping has been noted previously in vaccines and has not resulted in decreased safety or effectiveness; Canadian healthcare professionals possessing the vaccines may start using them now. No reports of serious or unexpected adverse events related to the vaccines have been reported in Canada.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For further information, refer to the following website: file://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2012/2012_164-eng.php",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Influenza Virus Vaccine",
"     </span>",
"     <span class=\"collapsible-date\">",
"      2012-2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The 2012-2013 influenza virus vaccine contains the same H1N1 virus as in the 2011-2012 vaccine, but different H3N2 and B viruses. The vaccine strains approved for this season in the United States are as follows: A/California/7/2009 (H1N1)-like virus, A/Victoria/361/2011 (H3N2)-like virus, and B/Wisconsin/1/2010-like virus. Because immunity to influenza virus declines over time, and because two of the three strains of the virus are different this year than last, persons should be vaccinated every year even if vaccinated during the previous season.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       In addition, a variant influenza A virus (H3N2v) is currently circulating in pigs and infecting humans. Immunization with the 2012-2013 seasonal influenza vaccine is not expected to provide protection against this virus.  Symptoms of H3N2v are generally similar to those of seasonal influenza infections.  Unfortunately, standard tests used to detect influenza virus cannot differentiate between H3N2v virus from seasonal influenza A (H3N2) virus and there is a potential for false negatives with antigen detection tests. Clinicians who suspect probable H3N2v virus should contact their local or state health department for additional testing for H3N2v at a state public health laboratory. A link to recent swine exposure (within 1 week) of symptom onset should be considered a probable H3N2v case. Antiviral treatment of H3N2v influenza is the same as seasonal influenza.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information refer to the following websites:",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"       FDA approves vaccines for the 2012-2013 influenza season:",
"       <a href=\"file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm315365.htm\" target=\"_blank\">",
"        file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm315365.htm",
"       </a>",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"       CDC, Interim Information about Human Infections with H3N2v Virus:",
"       <a href=\"file://www.cdc.gov/flu/swineflu/h3n2v-clinician.htm\" target=\"_blank\">",
"        file://www.cdc.gov/flu/swineflu/h3n2v-clinician.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9560252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Afluria&reg;;",
"     </li>",
"     <li>",
"      Fluarix&reg;;",
"     </li>",
"     <li>",
"      Flucelvax&reg;;",
"     </li>",
"     <li>",
"      FluLaval&reg;;",
"     </li>",
"     <li>",
"      Fluvirin&reg;;",
"     </li>",
"     <li>",
"      Fluzone&reg;;",
"     </li>",
"     <li>",
"      Fluzone&reg; High-Dose;",
"     </li>",
"     <li>",
"      Fluzone&reg; Intradermal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9560327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Agriflu&trade;;",
"     </li>",
"     <li>",
"      Fluad&trade;;",
"     </li>",
"     <li>",
"      Fluviral&reg;;",
"     </li>",
"     <li>",
"      Influvac&reg;;",
"     </li>",
"     <li>",
"      Intanza&reg;;",
"     </li>",
"     <li>",
"      Vaxigrip&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9560255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Inactivated (Viral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9600936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is important to note that influenza seasons vary in their timing and duration from year to year. In general, vaccination should begin soon after the vaccine becomes available and prior to onset of influenza activity in the community. However, vaccination should continue throughout the influenza season as long as vaccine is available. Unless noted, the ACIP does not have a preference for any given IIV formulation when used within their specified age indications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Immunization:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     I.M.:",
"     <i>",
"      Afluria&reg;, Fluarix&reg;, Flucelvax&reg;, FluLaval&reg;, Fluvirin&reg;, Fluzone&reg;:",
"     </i>",
"     0.5 mL/dose (1 dose per season)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Intradermal: Adults 18-64 years:",
"     <i>",
"      Fluzone&reg; Intradermal:",
"     </i>",
"     0.1 mL/dose (1 dose per season)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">",
"     Canadian labeling (products not available in U.S.):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.:",
"     <i>",
"      Agriflu&trade;, Fluviral&reg;, Vaxigrip&reg;:",
"     </i>",
"     0.5 mL/dose (1 dose per season)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., SubQ:",
"     <i>",
"      Influvac&reg;:",
"     </i>",
"     0.5 mL/dose (1 per season)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intradermal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Intanza&reg; 9 mcg/strain: Adults 18-59 years: 0.1 mL/dose (1 dose per season)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Intanza&reg; 15 mcg/strain: Adults &ge;60 years: 0.1 mL/dose  (1 dose per season)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9560266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/21/20824?source=see_link\">",
"      see \"Influenza virus vaccine (inactivated): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is important to note that influenza seasons vary in their timing and duration from year to year. In general, vaccination should begin soon after the vaccine becomes available and prior to onset of influenza activity in the community. However, vaccination should continue throughout the influenza season as long as vaccine is available. Unless noted, the ACIP does not have a preference for any given IIV formulation when used within their specified age indications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Immunization:",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Afluria&reg;:",
"     </i>",
"     Although FDA-approved for use in children &ge;5 years of age, the ACIP does not recommend use of Afluria&reg; in children &lt;9 years due to an increased incidence of fever and febrile seizures noted during the 2010-2011 influenza season. However, if other age-appropriate vaccines are not available, children 5-8 years of age who are also considered at risk for influenza complications may be given Afluria&reg;. The benefits and risks of this vaccine should be discussed with parents or caregivers prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 5-8 years: 0.5 mL/dose (1 or 2 doses per season; see",
"     <b>",
"      \"Note\"",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;9 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Fluarix&reg;:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 3-8 years: 0.5 mL/dose (1 or 2 doses per season; see",
"     <b>",
"      \"Note\"",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;9 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Fluzone&reg;:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6-35 months: 0.25 mL/dose (1 or 2 doses per season; see",
"     <b>",
"      \"Note\"",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 3-8 years: 0.5 mL/dose (1 or 2 doses per season; see",
"     <b>",
"      \"Note\"",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;9 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Fluvirin&reg;:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 4-8 years: 0.5 mL/dose (1 or 2 doses per season; see",
"     <b>",
"      \"Note\"",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;9 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">",
"     Canadian labeling (products not available in U.S.):",
"     <i>",
"      Agriflu&trade;, Fluviral&reg;, Vaxigrip&reg;:",
"     </i>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6-35 months: Manufacturer labeling: 0.25 mL/dose; NACI recommendation: 0.5 mL/dose (NACI, 2011) (1 or 2 doses per season; see",
"     <b>",
"      Note",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 3-8 years: 0.5 mL/dose (1 or 2 doses per season; see",
"     <b>",
"      \"Note\"",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;9 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Children 6 months to &lt;9 years who received a total of &ge;2 doses of seasonal influenza vaccine since July 1, 2010, need only 1 dose of the 2012-2013 seasonal influenza vaccine. If a child did not receive a total of &ge;2 doses of seasonal vaccine since July 1, 2010, if they have never received seasonal influenza vaccine (ie, this is their first season of vaccination), or if their vaccination status cannot be determined, they should receive 2 doses separated by &ge;4 weeks, in order to achieve satisfactory antibody response. Additional dosing considerations are provided when vaccination history is available prior to the 2010-2011 season; see current guidelines for additional information (CDC, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9600937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is important to note that influenza seasons vary in their timing and duration from year to year. In general, vaccination should begin soon after the vaccine becomes available and prior to onset of influenza activity in the community. However, vaccination should continue throughout the influenza season as long as vaccine is available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Immunization:",
"     </b>",
"     Adults &ge;65 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Afluria&reg;, Fluarix&reg;, Flucelvax&reg;, FluLaval&reg;, Fluvirin&reg;, Fluzone&reg;, Fluzone&reg; High-Dose:",
"     </i>",
"     I.M.: 0.5 mL/dose (1 dose per season).  The ACIP does not have a preference for any given IIV formulation when used within their specified age indications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Canadian labeling (product not available in U.S.):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     <i>",
"      Fluad&trade;:",
"     </i>",
"     I.M.: 0.5 mL/dose (1 dose per season)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     <i>",
"      Intanza&reg; 15 mcg/strain:",
"     </i>",
"     Intradermal: Refer to adult dosing",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9600938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Afluria&reg;: Hemagglutinin 45 mcg/0.5 mL (5 mL) [contains chicken egg protein, neomycin (may have trace amounts), polymyxin B (may have trace amounts), thimerosal]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FluLaval&reg;: Hemagglutinin 45 mcg/0.5 mL (5 mL) [contains chicken egg protein, thimerosal]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluvirin&reg;: Hemagglutinin 45 mcg/0.5 mL (5 mL) [contains chicken egg protein, neomycin (may have trace amounts), polymyxin B (may have trace amounts), thimerosal]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluzone&reg;: Hemagglutinin 45 mcg/0.5 mL (5 mL) [contains chicken egg protein, thimerosal]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Afluria&reg;: Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains chicken egg protein, neomycin (may have trace amounts), polymyxin B (may have trace amounts)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluarix&reg;: Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains chicken egg protein, gentamicin  (may have trace amounts), hydrocortisone  (may have trace amounts), may contain natural rubber/natural latex in prefilled syringe, polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flucelvax&reg;: Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains polysorbate 80, may contain natural rubber/natural latex in prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluvirin&reg;: Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains chicken egg protein, may contain natural rubber/natural latex in prefilled syringe, neomycin (may have trace amounts), polymyxin B (may have trace amounts)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluzone&reg;: Hemagglutinin 22.5 mcg/0.25 mL (0.25 mL); Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains chicken egg protein]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluzone&reg; High-Dose: Hemagglutinin 180 mcg/0.5 mL (0.5 mL) [contains chicken egg protein]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluzone&reg; Intradermal: Hemagglutinin 27 mcg/0.1 mL (0.1 mL) [contains chicken egg protein]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F13703758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluviral&reg;: Hemagglutinin 45 mcg/0.5 mL (5 mL) [contains chicken egg protein, thimerosal]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vaxigrip&reg;: Hemagglutinin 45 mcg/0.5 mL (5 mL) [contains chicken egg protein,   neomycin (may have trace amounts), thimerosal]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Agriflu&trade;: Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains chicken egg protein, neomycin (may have trace amounts), kanamycin (may have trace amounts), polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluad&trade;: Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains chicken egg protein, neomycin (may have trace amounts), kanamycin (may have trace amounts), polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Influvac&reg;: Hemagglutinin 45 mcg/0.5 mL (0.5 mL) [contains chicken egg protein, gentamicin (may have trace amounts), polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intanza&reg;: Hemagglutinin 27 mcg/0.1 mL (0.1 mL) [contains chicken egg protein, neomycin (may have trace amounts)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intanza&reg;: Hemagglutinin 45 mcg/0.1 mL (0.1 mL) [contains chicken egg protein, neomycin (may have trace amounts)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vaxigrip&reg;: Hemagglutinin 45 mcg/0.5 mL (0.25 mL, 0.5 mL) [contains chicken egg protein,   neomycin (may have trace amounts)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9560328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15840740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Fluarix&reg; Quadrivalent:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fluarix&reg; Quadrivalent: FDA approved December 2012; availability expected during the 2013-2014 influenza season.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fluarix&reg; Quadrivalent is an inactivated influenza virus vaccine approved for patients &ge;3 years of age. Seasonal quadrivalent influenza  vaccines contain two subtype A strains and two subtype B strains; trivalent influenza vaccines contain two subtype A strains and one subtype B strain.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9560343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Fluzone&reg; Intradermal, Intanza&reg; (Canadian availability):",
"     </i>",
"     For intradermal administration over the deltoid muscle only. Fluzone&reg; Intradermal should be shaken gently prior to use. Intanza&reg; should not be shaken prior to use. Hold system using the thumb and middle finger (do not place fingers on windows). Insert needle perpendicular to the skin; inject using index finger to push on plunger. Do not aspirate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Afluria&reg;, Fluarix&reg;, Flucelvax&reg;, FluLaval&reg;, Fluvirin&reg;, Fluzone&reg;, Fluzone&reg; High-Dose, Agriflu&trade; (Canadian availability), Fluad&trade; (Canadian availability), Fluviral&reg; (Canadian availability), Vaxigrip&reg; (Canadian availability):",
"     </i>",
"     For I.M. administration only. Inspect for particulate matter and discoloration prior to administration. Adults and older children should be vaccinated in the deltoid muscle using a &ge;1 inch needle length. Infants and young children &lt;12 months of age should be vaccinated in the anterolateral aspect of the thigh using a",
"     <sup>",
"      7",
"     </sup>",
"     /",
"     <sub>",
"      8",
"     </sub>",
"     inch to 1 inch needle length. Young children with adequate deltoid muscle mass should be vaccinated using a",
"     <sup>",
"      7",
"     </sup>",
"     /",
"     <sub>",
"      8",
"     </sub>",
"     inch to 1.25 inch needle. Do not inject into the gluteal region or areas where there may be a major nerve trunk. Suspensions should be shaken well prior to use. Some manufacturers recommend avoiding use if visible particles are present in the suspension after shaking. See manufacturer labeling for specific recommendations.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Influvac&reg; (Canadian availability):",
"     </i>",
"     May be administered by I.M. or deep subcutaneous injection. Shake well prior to use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Unless otherwise indicated in product labeling, jet injectors should",
"     <b>",
"      not",
"     </b>",
"     be used to administer inactivated influenza vaccines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     If a pediatric vaccine (0.25 mL) is inadvertently administered to an adult, an additional 0.25 mL should be administered to provide the full adult dose (0.5 mL). If the error is discovered after the patient has left, an adult dose should be given as soon as the patient can return. If an adult vaccine (0.5 mL) is inadvertently given to a child, no action needs to be taken.",
"     <i>",
"      Agriflu&trade; (Canadian availability):",
"     </i>",
"     If 0.25 mL dose is to be given, discard half the contained syringe volume prior to administration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     For patients at risk of hemorrhage following intramuscular injection, the ACIP recommends &ldquo;it should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered  by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection.&rdquo; Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. Separate vaccines should not be combined in the same syringe unless indicated by product specific labeling. Separate needles and syringes should be used for each injection. However, in general, vaccination should not be deferred if the brand name or route of the previous dose is not available or not known (CDC, 2011). Adolescents and adults should be vaccinated while seated or lying down. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9560341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Provide active immunity to influenza virus strains contained in the vaccine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends annual vaccination with the seasonal inactivated influenza vaccine (IIV) (injection) for all persons &ge;6 months of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     When vaccine supply is limited, target groups for vaccination (those at higher risk of complications from influenza infection and their close contacts) include the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Persons &ge;50 years of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Residents of nursing homes and other chronic-care facilities that house persons of any age with chronic medical conditions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adults and children with chronic disorders of the pulmonary or cardiovascular systems (except hypertension), including asthma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adults and children who have chronic metabolic diseases (including diabetes mellitus), hepatic disease, renal dysfunction, hematologic disorders, or immunosuppression (including immunosuppression caused by medications or HIV)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adults and children with cognitive or neurologic/neuromuscular conditions (including conditions such as spinal cord injuries or seizure disorders) which may compromise respiratory function, the handling of respiratory secretions, or that can increase the risk of aspiration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Children and adolescents (6 months to 18 years of age) who are receiving long-term aspirin therapy, and therefore, may be at risk for developing Reye's syndrome after influenza",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Women who are or will be pregnant during the influenza season",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Children 6-59 months of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Healthcare personnel",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Household contacts and caregivers of children &lt;5 years (particularly children &lt;6 months) and adults &ge;50 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Household contacts and caregivers of persons with medical conditions which put them at high risk of complications from influenza infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; American Indians/Alaska Natives",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Morbidly obese (BMI &ge;40)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     The Advisory Committee on Immunization Practices (ACIP) states that healthy, nonpregnant persons aged 2-49 years may receive vaccination with either the seasonal live, attenuated influenza vaccine (LAIV) (nasal spray) or the seasonal trivalent inactivated influenza vaccine (IIV) (injection).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9560326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fluarix&reg; may be confused with Flarex&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Influenza virus vaccine may be confused with flumazenil",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Influenza virus vaccine may be confused with tetanus toxoid and tuberculin products. Medication errors have occurred when tuberculin skin tests (PPD) have been inadvertently administered instead of tetanus toxoid products and influenza virus vaccine. These products are refrigerated and often stored in close proximity to each other.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fluarix [U.S., Canada, and multiple international markets] may be confused with Flarex brand name for fluorometholone [U.S. and multiple international markets] and Fluorex brand name for fluoride [France]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9560259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Frequency not defined. Adverse reactions in adults &ge;65 years of age may be greater using the high-dose vaccine, but are typically mild and transient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest tightness, facial edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills, drowsiness, fatigue, fever, headache, irritability, malaise, migraine, shivering",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Appetite decreased, diarrhea, nausea, sore throat, upper abdominal pain, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions (including bruising, erythema, induration, inflammation, pain, soreness [&le;64%; may last up to 2 days], pruritus, swelling, tenderness)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia (may start within 6-12 hours and last 1-2 days; incidence generally equal to placebo in adults; occurs more frequently than placebo in children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Red eyes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Earache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough, nasal congestion, nasopharyngitis, pharyngolaryngeal pain, rhinitis, upper respiratory tract infection, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports (limited to important or life-threatening): Allergic reactions, anaphylaxis, angioedema, convulsions, erythema multiforme, facial palsy (Bell&rsquo;s palsy), Guillain-Barr&eacute; syndrome (GBS), Henoch-Sch&ouml;nlein purpura, hypersensitivity reaction, limb paralysis, lymphadenopathy, myelitis (including encephalomyelitis and transverse myelitis), neuralgia, oculorespiratory syndrome (ORS; acute, self-limited reaction with ocular and respiratory symptoms), optic neuritis/neuropathy, paralysis, photophobia, serum sickness, Stevens-Johnson syndrome, syncope, tachycardia, thrombocytopenia, urticaria, vasculitis, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9560342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prior life-threatening reaction to previous influenza vaccination; hypersensitivity to any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fluviral&reg; (not available in U.S.): Canadian labeling: Additional contraindications: Presence of acute respiratory infection, other active infections, or serious febrile illness",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9600929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute illness: May consider deferring administration in patients with moderate or severe acute illness (with or without fever); may administer to patients with mild acute illness (with or without fever) (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from I.M. administration (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Febrile seizures: Postmarketing reports of increased incidence of fever and febrile seizures in children &lt;5 years of age has been observed with the use of the 2010 Southern Hemisphere formulation of the Afluria&reg; vaccine. Febrile events have also been reported in children 5 to &lt;9 years of age. Based on information from the CDC, an increased rate of febrile seizures has been reported in young children (&lt;5 years), especially among children 12 through 23 months of age, who received vaccination with inactivated influenza vaccine (IIV) and the 13-valent pneumococcal conjugate vaccine (PCV13) simultaneously. However, due to the risks associated with delaying either vaccine, administering them at separate visits or deviating from the recommended vaccine schedule is not currently recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Guillain-Barr&eacute; syndrome: Use with caution in patients with history of Guillain-Barr&eacute; syndrome (GBS); patients with history of GBS have a greater likelihood of developing GBS than those without. As a precaution, the ACIP recommends that patients with a history of GBS and who are at low risk for severe influenza complications, and patients known to have experienced GBS within 6 weeks following previous vaccination should generally not be vaccinated (consider influenza antiviral chemoprophylaxis in these patients). The benefits of vaccination may outweigh the potential risks in persons with a history of GBS who are also at high risk for complications of influenza (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV: Antigenic response may not be as great as expected in HIV-infected persons with CD4 cells &lt;100/mm",
"     <sup>",
"      3",
"     </sup>",
"     and viral copies of HIV type 1 &gt;30,000/mL (CDC, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurologic disorders: Some Canadian product labeling recommends delaying therapy in patients with active neurologic disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines: In order to maximize vaccination rates, the ACIP, as well as the Canadian National Advisory Committee on Immunization (NACI), recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered immunocompetence: Use with caution in severely-immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroid]); may have a reduced response to vaccination. Inactivated vaccine is preferred over live virus vaccine for household members, healthcare workers and others coming in close contact with severely-immunosuppressed persons requiring care in a protected environment (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Antibody responses may be lower in older adults &ge;65 years compared to younger adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chicken egg protein: Most products are manufactured with chicken egg protein (expressed as ovalbumin content). The ovalbumin content may vary from season to season and lot to lot of vaccine. Allergy to eggs must be distinguished from allergy to the vaccine. Recommendations are available from the CDC and NACI regarding influenza vaccination to persons who report egg allergies; however, a prior severe allergic reaction to influenza vaccine, regardless of the component suspected, is a contraindication to vaccination (CDC, 2012). NACI no longer considers an egg allergy as a contraindication to vaccination (NACI, 2011). Flucelvax&reg; is an inactivated influenza vaccine manufactured using cell culture technology and provides an alternative to vaccines cultured with chicken egg protein.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gentamicin: Some products are manufactured with gentamicin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kanamycin: Some products are manufactured with kanamycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: Packaging may contain natural latex rubber.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neomycin: Some products are manufactured with neomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polymyxin: Some products are manufactured with polymyxin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thimerosal: Some products contain thimerosal; hypersensitivity reactions may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Previous season vaccines: Influenza vaccines from previous seasons must not be used.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pneumococcal Conjugate Vaccine (13-Valent): May diminish the therapeutic effect of Influenza Virus Vaccine (Inactivated). Influenza Virus Vaccine (Inactivated) may diminish the therapeutic effect of Pneumococcal Conjugate Vaccine (13-Valent). Management: Immune response to these vaccines may be diminished when given concomitantly to patients 65 years old or older.  When practical, consider separating doses of these vaccines by 1 month or more for these patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9600925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B/C (manufacturer specific) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9600926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted with all products. When conducted, adverse events were not observed in animal studies. Inactivated influenza vaccine has not been shown to cause fetal harm and has been shown to be safe and effective when given to pregnant women. Following maternal immunization with the influenza virus vaccine, vaccine specific antibodies are observed in the newborn.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Pregnant women are at an increased risk of complications from influenza infection (Rasmussen, 2008). Influenza vaccination with the inactivated influenza vaccine (IIV) is recommended for all women who are or will become pregnant during the influenza season and who do not otherwise have contraindications to the vaccine. Pregnant women should observe the same precautions as nonpregnant women to reduce the risk of exposure to influenza and other respiratory infections. When vaccine supply is limited, focus on delivering the vaccine should be given to women who are pregnant or will be pregnant during the flu season, as well as mothers of newborns and contacts or caregivers of children &lt;5 years of age (CDC, 2010). Most available studies show a decrease in influenza-related illnesses in pregnant women as well as children &lt;6 months of age following maternal vaccination during pregnancy, thereby supporting current recommendations that all pregnant women should be vaccinated (Zaman, 2008).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to refer women exposed to the influenza vaccine during pregnancy to the",
"     <i>",
"      Vaccines and Medications in Pregnancy Surveillance System",
"     </i>",
"     (VAMPSS) by contacting The Organization of Teratology Information Specialists (OTIS) at (877) 311-8972. Women exposed to Flulaval&reg; or Fluarix&reg; during pregnancy may also contact the GlaxoSmithKline registry at 888-452-9622. Healthcare providers may enroll women exposed to Fluzone&reg; Intradermal during pregnancy in the Sanofi Pasteur vaccination registry at 800-822-2463.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9600927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9600928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if inactivated influenza vaccine is excreted into breast milk; however, breast-feeding is not a contraindication to vaccination. Postpartum women may be vaccinated with either IIV or LAIV. When vaccine supply is limited, focus on delivering the vaccine should be given to women who are pregnant or will be pregnant during the flu season, as well as mothers of newborns and contacts or caregivers of children &lt;5 years of age (CDC, 2010). Breast-feeding infants should be vaccinated according to the recommended schedules (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Device",
"     </b>",
"     (Fluzone Intradermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9 mcg/strain (0.1 mL): $19.91",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13315042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion. For those individuals who report a history of egg allergy but it is determined that the inactivated vaccine can be used, observe vaccine recipient for at least 30 minutes after receipt of vaccine.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9600931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes immunity to seasonal influenza virus by inducing specific antibody production. Each year the formulation is standardized according to the U.S. Public Health Service. Preparations from previous seasons must not be used.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9600933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Protective antibody titers achieved ~3 weeks after vaccination",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Protective antibody titers persist approximately &ge;6 months. Elderly: Protective antibody titers may fall &le;4 months after vaccination.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ashkenazi S, Vertruyen A, Arisegui J, et al, &ldquo;Superior Relative Efficacy of Live Attenuated Influenza Vaccine Compared With Inactivated Influenza Vaccine in Young Children With Recurrent Respiratory Tract Infections,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2006, 25(10):870-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/61/985/abstract-text/17006279/pubmed\" id=\"17006279\" target=\"_blank\">",
"        17006279",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bentley DW, &ldquo;Vaccinations,&rdquo;",
"      <i>",
"       Clin Geriatr Med",
"      </i>",
"      , 1992, 8(4):745-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/61/985/abstract-text/1423132/pubmed\" id=\"1423132\" target=\"_blank\">",
"        1423132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Prevention and Control of Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-8):1-62. Available at:",
"      <a href=\"file://www.cdc.gov/mmwr/PDF/rr/rr5908.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/PDF/rr/rr5908.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/61/985/abstract-text/20689501/pubmed\" id=\"20689501\" target=\"_blank\">",
"        20689501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Prevention and Control of Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), United States, 2012-13 Influenza Season,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2012, 61(32):613-7. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6132a3.htm?s_cid=mm6132a3_w\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6132a3.htm?s_cid=mm6132a3_w",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/61/985/abstract-text/21866086/pubmed\" id=\"21866086\" target=\"_blank\">",
"        21866086",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/61/985/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Tiered Use of Inactivated Influenza Vaccine in the Event of a Vaccine Shortage,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2005, 54(30):749-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/61/985/abstract-text/16079741/pubmed\" id=\"16079741\" target=\"_blank\">",
"        16079741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Update on Febrile Seizures in Children Following Vaccination With Influenza Vaccines and Pneumococcal Vaccines&rdquo;, updated October 2011. Available at",
"      <a href=\"file://www.cdc.gov/vaccinesafety/Concerns/FebrileSeizures.html\" target=\"_blank\">",
"       file://www.cdc.gov/vaccinesafety/Concerns/FebrileSeizures.html",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gardner P and Schaffner W, &ldquo;Immunization of Adults,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 328(17):1252-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/61/985/abstract-text/8464436/pubmed\" id=\"8464436\" target=\"_blank\">",
"        8464436",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Advisory Committee on Immunization (NACI), &ldquo;Statement on Seasonal Influenza Vaccine for 2011-2012,&rdquo;",
"      <i>",
"       Can Commun Dis Rep",
"      </i>",
"      , 2011, 37(ACS-5):1-55. Available at file://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/11vol37/acs-dcc-5/index-eng.php",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/61/985/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rasmussen SA, Jamieson DJ, and Bresee JS, \"Pandemic Influenza and Pregnant Women,\"",
"      <i>",
"       Emerg Infect Dis",
"      </i>",
"      , 2008, 14(1):95-100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/61/985/abstract-text/18258087/pubmed\" id=\"18258087\" target=\"_blank\">",
"        18258087",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/61/985/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/61/985/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Food and Drug Administration, &ldquo;FDA Updated Communication on Use of Jet Injectors With Inactivated Influenza Vaccines&rdquo;, October 26, 2011. Available at",
"      <a href=\"file://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm276773.htm\" target=\"_blank\">",
"       file://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm276773.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zaman K, Roy E, Arifeen SE, et al, &ldquo;Effectiveness of Maternal Influenza Immunization in Mothers and Infants,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 9(15):1555-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/61/985/abstract-text/18799552/pubmed\" id=\"18799552\" target=\"_blank\">",
"        18799552",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9055 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-17F8E0A872-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_61_985=[""].join("\n");
var outline_f0_61_985=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14959458\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560252\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560327\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560255\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600936\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560266\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600937\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897886\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897887\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600938\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13703758\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560328\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15840740\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560343\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560341\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560326\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560259\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560342\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600929\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299519\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221011\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600925\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600926\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600927\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600928\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570492\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13315042\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600931\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600933\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9055\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9055|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/53/16209?source=related_link\">",
"      Influenza virus vaccine (inactivated): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/21/20824?source=related_link\">",
"      Influenza virus vaccine (inactivated): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_61_986="Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy";
var content_f0_61_986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/61/986/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/61/986/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/61/986/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/61/986/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/61/986/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/61/986/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/61/986/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an HIV-infected patient is prescribed antiretroviral therapy, it is important to review potential side effects of these medications. Patients need to understand what symptoms to anticipate and when they should seek help for adverse events, which can sometimes be associated with significant morbidity. It is important for clinicians to be responsive to the concerns of the patient, since side effects can lead to decreased adherence and drug resistance.",
"   </p>",
"   <p>",
"    This topic will highlight the major adverse events associated with use of specific medications; however, it is not intended to be a comprehensive review of all potential adverse events. Clinicians are advised to consult the drug information topics within UpToDate for individual drugs and other information resources, such as package inserts.",
"   </p>",
"   <p>",
"    Efficacy of various antiretroviral therapy regimens, patient evaluation, counseling regarding side effects, and laboratory monitoring are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=see_link\">",
"     \"Patient monitoring during HIV antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3370?source=see_link\">",
"     \"Considerations prior to initiating antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects with ART are common; however, many side effects improve over time with continued administration. It is critically important for the clinician to differentiate between mild versus potentially serious adverse events when making decisions about continuing therapy.",
"   </p>",
"   <p>",
"    Some drug reactions are progressive with continued exposure and can be potentially life threatening. The patient must be counseled regarding these potentially serious adverse events and be told to stop therapy until the provider can evaluate them. However, drug cessation is advised with some trepidation since repeated stops with prolonged \"unstructured treatment interruptions\" promote resistance. Serious reactions are rare and are included in black box warnings from the Federal Drug Administration (FDA). Major serious or life-threatening reactions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       Abacavir",
"      </a>",
"      hypersensitivity reaction. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Abacavir hypersensitivity reaction'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Stevens-Johnson syndrome (SJS) or toxic epidermal necrosis (TEN), which is most commonly associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      , but also reported with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"       etravirine",
"      </a>",
"      , all PIs (except",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"       saquinavir",
"      </a>",
"      ) and many NRTIs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatic necrosis due to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=see_link\">",
"       \"Drugs and the liver: Patterns of drug-induced liver injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatitis B flares due to discontinuation of agents active against both HIV and HBV (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      ) due to immune reconstitution inflammatory syndrome or due to HBV resistance to the NRTI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"       \"Treatment of hepatitis B in the HIV-infected patient\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"       \"Immune reconstitution inflammatory syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Progressive ascending neuromuscular weakness (similar to Guillain Barr&eacute; syndrome) usually due to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35864?source=see_link\">",
"       \"Epidemiology, pathogenesis and clinical features of HIV-associated neuropathies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lactic acidosis with weight loss, fatigue, and gastrointestinal symptoms, which is associated with mitochondrial toxicity secondary to certain nucleoside analogs. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Nucleoside analogs'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even mild to moderate symptoms can also effect a patient's quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients need to be reassured that the provider will address symptoms as they arise and that many side effects can be easily addressed (eg, Imodium for diarrhea).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ADHERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are started on ART need to be counseled about the importance of adherence prior to initiation of medications [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Patients need to understand that lack of adherence may lead to drug resistance. Several factors can lead to poor adherence, including drug toxicity, complexity of the regimen, and other factors, such as substance abuse or mental illness.",
"   </p>",
"   <p>",
"    Adherence and risk of drug resistance is complicated due to variations in drug pharmacology, genetic barriers, and drug potency. The commonly quoted adage is the need to take 95 percent of prescribed doses [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/4\">",
"     4",
"    </a>",
"    ]. However, this observation was shown with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    -based ART, which is no longer used. The half-lives of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    and the preferred non-nucleoside reverse transcriptase inhibitor (NNRTI),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , are long (several days or weeks); therefore, 70 percent adherence with one to two days \"off\" does not result in failure to suppress viremia. However, NVP and EFV have low barriers to resistance so longer interruptions are likely to eliminate the future value of both drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Generally speaking,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted protease inhibitors have improved pharmacokinetics allowing once daily dosing. Protease inhibitors are also associated with less overall drug resistance than the other five classes of antiretroviral medications. Thus, poor adherence with a protease inhibitor-containing regimen may lead to virologic failure, but not necessarily drug resistance due to the requisite for multiple mutations before drug potency is affected. Despite these observations, all patients should be encouraged to adhere to their regimen as much as possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLASS SPECIFIC SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug intolerance was the leading reason for changing ART in a study of more than 1800 treatment-naive patients from the Swiss HIV Cohort Study [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/6\">",
"     6",
"    </a>",
"    ]. Adverse reactions can sometimes apply to all or nearly all members of a drug class. Examples include mitochondrial toxicity and hyperlipidemia (",
"    <a class=\"graphic graphic_table graphicRef66245 graphicRef77005 \" href=\"UTD.htm?6/33/6686\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NUCLEOSIDE ANALOGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the nucleoside analog class is associated with mitochondrial toxicity, which can manifest as lactic acidosis or symptomatic hyperlactatemia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Side effects can include weight loss, nausea, vomiting, right upper quadrant pain, abdominal bloating, myalgias, and fatigue. However, the drugs within this class vary in their propensity to lead to mitochondrial toxicity. The drugs of greatest concern include the thymidine analogues (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    ); this is one of the major reasons that these drugs are infrequently used for initial therapy. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=see_link\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common side effects related to specific nucleoside analogs are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Abacavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     Abacavir",
"    </a>",
"    (Ziagen; ABC) is generally well tolerated. However, abacavir can be associated with a drug hypersensitivity reaction that is seen in 3 to 5 percent of patients within the first six weeks of drug exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Abacavir hypersensitivity reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms and signs of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    hypersensitivity reaction (AHR) may include fever, rash, and gastrointestinal and respiratory complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/10\">",
"     10",
"    </a>",
"    ]. The severity often increases with subsequent doses. Immediate discontinuation of abacavir is needed if the hypersensitivity reaction is suspected; rechallenge can be life-threatening and is contraindicated [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21049?source=see_link\">",
"     \"Abacavir hypersensitivity reaction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the symptoms and signs of AHR can be difficult to distinguish from those of concomitant infection or reaction to other drugs. As a result, overdiagnosis of AHR has led to an inaccurate estimation of true prevalence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Screening for AHR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several advances have improved the ability to predict and accurately diagnose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    hypersensitivity reaction (AHR). In 2002, an association between AHR and a specific HLA background was described in two separate studies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In addition, abacavir patch testing was designed to identify patients who had an immunologically mediated hypersensitivity reaction, without the risks of systemic rechallenge. Patch testing, however, cannot be used to screen for AHR in a patient who has not been exposed to the drug.",
"   </p>",
"   <p>",
"    The benefits of prospective screening with HLA-B*5701 testing has been demonstrated in two studies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/10,15\">",
"     10,15",
"    </a>",
"    ]. In a large double-blind, prospective, randomized study (PREDICT-1), 1956 patients were randomly assigned to undergo prospective HLA-B*5701 screening or no screening prior to initiating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    -containing ART [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/10\">",
"     10",
"    </a>",
"    ]. Those patients in the screening arm who had a positive screening test were excluded from taking abacavir. All study participants were followed prospectively for six weeks for evidence of AHR. Abacavir patch testing was also performed on patients with a clinical suspicion of abacavir hypersensitivity to confirm the diagnosis. The following results were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of HLA-B*5701 was 5.6 percent.",
"     </li>",
"     <li>",
"      Screening eliminated immunologically confirmed AHR in the prospective screening group. Thus, the negative predictive value was 100 percent.",
"     </li>",
"     <li>",
"      Clinically diagnosed AHR occurred in 7.8 percent of the control group; 2.7 percent of these reactions were confirmed by patch testing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data demonstrate that HLA-B*5701 testing can be used to prevent AHR. All major guidelines from the US, Europe and Australia recommend screening prior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    initiation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/16\">",
"     16",
"    </a>",
"    ], and this is now routinely done in all clinics. Abacavir should not be initiated in a patient with a positive screening test; an abacavir allergy should be recorded in the medical record for anyone with a positive genetic test result [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Although abacavir hypersensitivity is less common in African-Americans, this genetic marker appears to have excellent performance characteristics in this patient population as well [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A negative screening test virtually eliminates the risk of AHR. Nevertheless, it is appropriate to warn the patient of this risk even with a negative screening test [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/19\">",
"     19",
"    </a>",
"    ].If HLA-B*5701 testing is not available, then it is reasonable to initiate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    with patient counseling regarding potential signs of AHR, including fever, malaise, rash, and flu-like symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients should be advised to contact their provider as soon as possible if they develop typical symptoms, since it is important to clarify if the patient has an intercurrent illness or possible drug hypersensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Emtricitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     Emtricitabine",
"    </a>",
"    (Emtriva; FTC) is extremely well-tolerated. This drug is also active against HBV infection so drug discontinuation can cause a flare of hepatitis that can be fatal. This drug also has a black-box warning for lactic acidosis, but reported cases are very rare. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     \"Emtricitabine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Lamivudine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    (Epivir; 3TC) is extremely well tolerated. This drug is active versus HBV so drug discontinuation or the development of HBV drug resistance can cause a flare of HBV hepatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     \"Lamivudine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Didanosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     Didanosine",
"    </a>",
"    (Videx; ddI) can cause pancreatitis; the risk of this adverse event appears to be dose-related and was more common in earlier years when dosing exceeded that used today (eg, &gt;400 mg daily).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis of 17 ACTG studies yielded a relatively low overall rate of 0.61 per 100 person years for clinical pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/20\">",
"       20",
"      </a>",
"      ]. Of the various combinations of dual NRTIs studied,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      were associated with the highest rates of pancreatitis.",
"     </li>",
"     <li>",
"      In the EuroSIDA database, there were 43 pancreatic events in 9678 individuals for an incidence of",
"      <span class=\"nowrap\">",
"       1.27/1000",
"      </span>",
"      person-years of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/21\">",
"       21",
"      </a>",
"      ]. In this large database, collected since 2001, there was no evidence of an association of pancreatitis with cumulative exposure to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      , or the combination of both drugs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these data, the risk of pancreatitis appears low to negligible; however, patients should be advised to contact their provider if they develop abdominal pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/3/63?source=see_link\">",
"     \"Evaluation of abdominal pain in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of drug-related neuropathy correlates directly with the degree of mitochondrial toxicity of particular NRTIs; as noted above, dideoxynucleoside agents carry the greatest degree of concern. Combination therapy with both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    are associated with the highest risk of peripheral neuropathy and are no longer recommended as components of first-line therapy for",
"    <span class=\"nowrap\">",
"     HIV/AIDS.",
"    </span>",
"    Ongoing drug exposure can lead to severe disabling symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/56/29577?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and treatment of HIV-associated peripheral neuropathy\", section on 'Role of drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cumulative use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    is also associated with non-cirrhotic portal hypertension, which can lead to variceal bleeding and death [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     Didanosine",
"    </a>",
"    is no longer considered a first line nucleoside analog agent. If prescribed, patients should take ddI (400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    on an empty stomach. Those who weigh less than 60 kg should receive a lower dose of 250",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    They should not take ddI with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    or with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     \"Didanosine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Stavudine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     Stavudine",
"    </a>",
"    (Zerit; d4T) is associated with lactic acidosis, lipoatrophy, pancreatitis and peripheral neuropathy, particularly when used in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Didanosine'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/3/63?source=see_link\">",
"     \"Evaluation of abdominal pain in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/56/29577?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and treatment of HIV-associated peripheral neuropathy\", section on 'Role of drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exposure to certain NRTIs is a major risk factor associated with lipoatrophy, possibly due to NRTI-induced inhibition of mitochondrial DNA polymerase gamma. In vitro and in vivo studies suggest that thymidine analogues, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    in particular, play an important role in pathogenesis of lipoatrophy. Clinical manifestations can include loss of buccal fat and thinning of the extremities. Stavudine also causes hypertriglyceridemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\", section on 'Antiretroviral therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=see_link\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     \"Stavudine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     Stavudine",
"    </a>",
"    is no longer considered a first line nucleoside analog agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Tenofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    (Viread; TDF) is very well tolerated with minimal nephrotoxicity reported in early trials. Postmarketing surveillance covering more than 455,392 person-years of tenofovir exposure showed a serious renal event in less than 0.5 percent of patients and elevations of creatinine in 2.2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/24\">",
"     24",
"    </a>",
"    ]. Although uncommon, Fanconi syndrome and acute kidney injury have been reported; in one case series of 13 patients, histologic findings on biopsy demonstrated changes consistent with acute tubular necrosis with evidence of mitochondrial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients on tenofovir should be counseled regarding the need for regular monitoring of renal function and urinalysis.",
"   </p>",
"   <p>",
"    TDF is active versus hepatitis B virus and advocated in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    (or with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ) for patients who have HBV coinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is some evidence that TDF treatment alters bone metabolism predisposing to osteoporosis with long-term use [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3370?source=see_link\">",
"     \"Considerations prior to initiating antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     \"Tenofovir: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Zidovudine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    (Retrovir; AZT) can lead to gastrointestinal intolerance, headaches, and asthenia. Some of these adverse events, particularly headache, may improve with ongoing administration.",
"   </p>",
"   <p>",
"    Since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    can also lead to anemia, patients should be counseled to contact their provider if they should develop dyspnea on exertion or shortness of breath. A complete blood count should be monitored since zidovudine can also cause neutropenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3370?source=see_link\">",
"     \"Considerations prior to initiating antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     \"Zidovudine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although all three agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    ) of this class have the potential to cause rash and hepatotoxicity, most of the data concern nevirapine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Efavirenz",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    (Sustiva; EFV) can commonly lead to central nervous system toxicity, such as headaches, nightmares, and a feeling of being \"hung over\" or &ldquo;disassociated.&rdquo; Patients should be advised to avoid driving or operating heavy machinery if they have onset of this latter symptom, which usually resolves within one to three weeks of dosing. In one study of the neurologic symptoms associated with efavirenz use, 12 of 303 patients (6 percent) discontinued the drug due to central nervous system (CNS) toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/27\">",
"     27",
"    </a>",
"    ]. Another study evaluated treatment changes related to toxicity in 508 patients who had achieved viral suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/28\">",
"     28",
"    </a>",
"    ]. The most frequently reported adverse events involved the CNS (23 percent) and were only seen in patients taking efavirenz-based ART. This side effect is noted in about half of patients, the change is noted on the day treatment is started and it usually resolves over a period of two to three weeks. Patients should also be counseled that efavirenz can lead to mood changes, feelings of depression and nightmares. Some authorities consider major depression or suicide ideation to be contraindications to efavirenz use.",
"   </p>",
"   <p>",
"    Skin rash is another relatively common side effect (15 to 27 percent), but most patients can be &ldquo;treated through.&rdquo; Patients need to understand that they should contact their provider if a rash appears so the clinician can further evaluate whether the rash is severe enough to warrant discontinuation.",
"   </p>",
"   <p>",
"    Other side effects include hyperlipidemia and hepatotoxicity with increased transaminase levels. Patients should be counseled regarding the signs and symptoms of hepatotoxicity.",
"   </p>",
"   <p>",
"    Female patients must be advised to avoid pregnancy while taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , since its use is associated with teratogenicity resulting in neural tube disorders when taken in the first trimester. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     \"Efavirenz: Drug information\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians can also advise symptomatic patients to take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    on an empty stomach since food improves absorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Nevirapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The side effects of greatest concern with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    (Viramune) use are rash",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hepatotoxicity. About 15 percent develop a rash although this is only severe enough in one percent of all patients to require discontinuation. Patients should be counseled to contact a medical provider immediately if a diffuse rash should occur. Associated signs that may suggest nevirapine hypersensitivity syndrome include oral blistering and fever. Certain genetic factors, such as HLA type, may affect the risk of nevirapine hypersensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Development of a simple rash secondary to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    does not preclude a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/30\">",
"     30",
"    </a>",
"    ]. Development of Stevens-Johnson syndrome should result in avoidance of the class as a whole [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should also be instructed regarding symptoms of hepatotoxicity, including any of the following: right upper quadrant pain, nausea, vomiting, fatigue, weight loss, and jaundice.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    should NOT be initiated in men with a baseline CD4 count &gt;400",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    or women with a CD4 count &gt;250",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    since these represent major risk factors for hepatic necrosis. However, two studies in treatment-experienced patients have demonstrated that switching to nevirapine from another regimen appears safe, even after immune reconstitution [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     \"Nevirapine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4007170\">",
"    <span class=\"h2\">",
"     Rilpivirine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"     Rilpivirine",
"    </a>",
"    is generally well tolerated; the most common adverse drug reactions to rilpivirine in the phase 3 clinical trials were depression, insomnia, headache and rash. However, rash led to drug discontinuation in less than 1 percent of study participants [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Delavirdine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"     Delavirdine",
"    </a>",
"    (Rescriptor; DLV) is associated with headache, fever, and nausea; rash is seen in a significant minority of patients. This drug is uncommonly prescribed due to the need for three times daily dosing. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"     \"Delavirdine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Etravirine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adverse events that occurred during initial clinical trials with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    included rash (9 percent) (including rare patients with Stevens-Johnson Syndrome or erythema multiforme) and nausea. Rash occurred primarily in the second week of therapy and was infrequent after week four. Rash generally resolved within one to two weeks of continued dosing. Other relatively uncommon side effects include hepatoxicity, and hyperlipidemia. CNS toxicity is significantly less common than with EFV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROTEASE INHIBITORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Atazanavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects associated with use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    (Reyataz; ATV) include rash and nausea.",
"   </p>",
"   <p>",
"    Patients need to be advised that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    use may also lead to medically inconsequential jaundice that will easily resolve with drug discontinuation. However, patients need to be informed that they should contact their provider should this occur so the diagnosis can be confirmed. An elevated indirect bilirubin confirms the diagnosis of hyperbilirubinemia that is medically inconsequential; an elevated direct bilirubin would infer an alternate diagnosis and the possibility of liver injury. Patients at high risk for cardiovascular disease should be counseled regarding the favorable lipid profile of ATV and should be encouraged to follow a nutritious diet and to exercise. Note that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted atazanavir is preferred for overall greater treatment efficacy although ritonavir leads to a modest increase in serum lipids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?8/51/9013?source=see_link\">",
"     \"Atazanavir: Patient drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Darunavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     Darunavir",
"    </a>",
"    (Prezista; DRV) is associated with gastrointestinal symptoms (nausea, vomiting, diarrhea) and rash. Darunavir contains a sulfonamide moiety and should be used with caution in patients with a known sulfonamide allergy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?32/26/33189?source=see_link\">",
"     \"Darunavir: Patient drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Fosamprenavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adverse events associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    (Lexiva; FPV) include gastrointestinal symptoms (nausea, vomiting and diarrhea) and rash, which is usually mild [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?32/5/32853?source=see_link\">",
"     \"Fosamprenavir: Patient drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Indinavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    (Crixivan; IDV) include gastrointestinal symptoms, dry eyes and mouth, and nephrolithiasis. Patients must be advised regarding potential symptoms of renal colic; ingestion of more than 48 oz of fluid daily decreases the risk of this adverse outcome.",
"   </p>",
"   <p>",
"    Indirect hyperbilirubinemia is also commonly seen on laboratory monitoring, but clinical jaundice is uncommon. Patients can take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    without regard to meals if pharmacokinetic boosting of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    is employed. This drug is rarely used and is not recommended by the 2009 DHHS Guidelines or the 2010 IAS-USA Guidelines. (See",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?3/28/3525?source=see_link\">",
"     \"Indinavir: Patient drug information\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Lopinavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lopinavir (Kaletra; LPV) is associated with nausea, headache, and diarrhea. This agent is the PI that is most clearly associated with hyperlipidemia and risk of cardiovascular disease. It also has relatively poor gastrointestinal tolerance compared with alternative PIs such as",
"    <span class=\"nowrap\">",
"     DRV/r",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     ATV/r.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Nelfinavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    most common side effect with use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    (Viracept; NFV) is diarrhea. Patients should take nelfinavir with meals. This PI is antiquated due to reduced potency and should not be used in contemporary practice except in unusual circumstances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Ritonavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    (Norvir; RTV) was first introduced, it was dosed at 600 mg twice daily as a full independent component of ART. However, it became quickly evident that ritonavir was associated with significant side effects, including nausea, diarrhea, altered taste, circumoral paresthesia, and peripheral paresthesia.",
"   </p>",
"   <p>",
"    Subsequently the main role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    switched to a \"pharmacologic enhancer\" by inhibiting the cytochrome p450 3A4 isoenzymes and thereby increasing serum levels of other protease inhibitors. Use of ritonavir at a low dose for pharmacokinetic boosting is much better tolerated. (See",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?5/35/5686?source=see_link\">",
"     \"Ritonavir: Patient drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Saquinavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common side effects associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    (Invirase; SQV) are gastrointestinal in nature (nausea, vomiting and diarrhea). (See",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?20/34/21029?source=see_link\">",
"     \"Saquinavir: Patient drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Tipranavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principle adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    (Aptivus; TPV) include nausea, diarrhea, hepatotoxicity, and rash. Tipranavir should be used with caution in patients with a known sulfonamide allergy since tipranavir contains a sulfonamide component. Hepatotoxicity is more frequent and severe than with other PIs and hepatic insufficiency is a contraindication. Patients should also be instructed regarding symptoms of hepatotoxicity, including any of the following symptoms: right upper quadrant pain, nausea, vomiting, fatigue, and jaundice.",
"   </p>",
"   <p>",
"    Intracranial hemorrhage has also been reported among patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    , although the relationship of this adverse event to tipranavir is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     \"Tipranavir: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     FUSION INHIBITORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Enfuvirtide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     Enfuvirtide",
"    </a>",
"    (Fuzeon; T-20) is associated with mild to moderate hypersensitivity reactions at the injection site, including erythema, induration, nodules and cysts. Biopsies of these injection sites have demonstrated inflammatory infiltrates surrounding deposits of drug [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients should be instructed to rotate injection sites. Topical steroid creams can also be considered for local site reactions. Many patients simply cannot tolerate these injections. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=see_link\">",
"     \"Enfuvirtide: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     CCR5 INHIBITORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Maraviroc",
"    </span>",
"    &nbsp;&mdash;&nbsp;In clinical trials of highly treatment-experienced patients with advanced AIDS, the most common adverse reactions associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    (Selzentry; MVC) included cough, pyrexia, upper respiratory infections, rash, musculoskeletal symptoms, lightheadedness and abdominal pain. Failure to make dose adjustments with concurrent use of a CYP3A4 inhibitor and use of maraviroc in renal failure was associated with increased side effects. Better understanding of the side effects associated with maraviroc will come with the post-marketing experience.",
"   </p>",
"   <p>",
"    The US Federal Drug Administration is requiring long-term follow-up studies to examine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    's side effect profile more closely in terms of cardiovascular effects and liver toxicity. Patients should be instructed to contact their provider if they have any onset of cardiac symptoms, such as chest pain. Patients should also be educated on the symptoms of hepatotoxicity (eg, right upper quadrant pain, nausea, vomiting, jaundice, and fatigue) and instructed to contact their provider as soon as possible should symptoms consistent with hepatotoxicity ensue. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32918?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: CCR5 antagonists\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     INTEGRASE INHIBITORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Raltegravir",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    (Isentress; RGV) is very well tolerated. Side effects have included nausea, headache, and diarrhea. There are rare cases of myositis but cause and effect is not clearly established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     PHARMACOGENOMICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacogenomics is a promising field that examines the influence of genetic variation on drug response in patients. Preliminary data suggest that the use of pharmacogenomics may help to avert adverse drug-related events [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    is primarily metabolized by cytochrome P450 2B6 (CYP2B6). High plasma concentrations are associated with a G to T polymorphism at position 516 (516G to T) of CYP2B6 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. One study assessed CYP2B6 genotypes in 456 HIV-infected patients who were receiving or about to receive efavirenz treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?0/61/986/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients with the 516G to T polymorphism were given a dose as low as 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of efavirenz. Central nervous system-related side effects of efavirenz improved with dose reduction in 10 of 14 patients. However, this strategy is considered experimental and the test noted is not generally available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/44/22210?source=see_link\">",
"       \"Patient information: Starting treatment for HIV (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=see_link\">",
"       \"Patient information: HIV/AIDS (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/31/15861?source=see_link\">",
"       \"Patient information: Initial treatment of HIV (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/56/2946?source=see_link\">",
"       \"Patient information: Tips for taking HIV medications (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When an HIV-infected patient is initiated on antiretroviral therapy, it is important to review potential side effects of these medications. Patients need to understand what symptoms to anticipate and when they should seek help for adverse events, which can be associated with significant morbidity. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be interviewed regarding their level of adherence at every clinic visit in a non-judgmental manner. The link between poor adherence and drug resistance should be clearly communicated. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Adherence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be instructed to contact their provider about any troubling side effects, but should not stop the regimen until speaking with the provider. Potential exceptions may include onset of serious rash or symptoms of hepatotoxicity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be educated about side effects that can infer onset of mitochondrial toxicity, such as weight loss, nausea, vomiting, right upper quadrant pain, or abdominal bloating. This is particularly important for patients who are taking nucleoside analogs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      , all drugs that are now rarely used. Peripheral neuropathy can also be seen with stavudine or didanosine; ongoing drug administration can lead to disabling symptoms. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Nucleoside analogs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       Abacavir",
"      </a>",
"      can be associated with a drug hypersensitivity reaction that is seen in 3 to 5 percent of patients within the first six weeks of drug exposure. Prominent symptoms include fever, rash, and myalgias. However, genetic screening for HLA-B*5701 allows determination of those at risk for this adverse event. Abacavir should not be initiated in a patient with a positive screening test. Although a negative screening test virtually eliminates the risk of drug hypersensitivity, it is appropriate to warn the patient of the symptoms of hypersensitivity. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Abacavir hypersensitivity reaction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Agents within the non-nucleoside reverse transcriptase inhibitor class can be associated with rash and hepatotoxicity, although most data highlight the role of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      . Patients need to be educated about the symptoms of hepatotoxicity and hypersensitivity syndromes and be encouraged to see medical evaluation promptly. Patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      must be counseled regarding symptoms of dizziness with initiation of this agent; nightmares and depressive symptoms may develop after chronic use. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Non-nucleoside reverse transcriptase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common side effects of the protease inhibitor class include gastrointestinal symptoms, such as nausea, vomiting and diarrhea. All protease inhibitors except ATV are associated with hyperlipidemia. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Protease inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic side effects are uncommon with the use of fusion inhibitors, although injection site reactions can be particularly troubling. Rotation of injection sites can be modestly helpful. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Fusion inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The side effects associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"       maraviroc",
"      </a>",
"      are not yet clear. In clinical trials in patients with advanced AIDS, symptoms included cough, pyrexia, upper respiratory infections, rash, musculoskeletal symptoms, lightheadedness and abdominal pain. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'CCR5 inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The integrase inhibitor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      is very well-tolerated. Side effects have included nausea, headache, and diarrhea. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Integrase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/1\">",
"      Mannheimer SB, Wold N, Gardner EM, et al. Mild-to-moderate symptoms during the first year of antiretroviral therapy worsen quality of life in HIV-infected individuals. Clin Infect Dis 2008; 46:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/2\">",
"      Mannheimer S, Friedland G, Matts J, et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002; 34:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/3\">",
"      Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 2001; 15:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/4\">",
"      Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/5\">",
"      Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/6\">",
"      Vo TT, Ledergerber B, Keiser O, et al. Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008; 197:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/7\">",
"      Henry K. The case for more cautious, patient-focused antiretroviral therapy. Ann Intern Med 2000; 132:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/8\">",
"      Falc&oacute; V, Rodr&iacute;guez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 2002; 34:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/9\">",
"      C&ocirc;t&eacute; HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/10\">",
"      Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/11\">",
"      Escaut L, Liotier JY, Albengres E, et al. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS 1999; 13:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/12\">",
"      Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/13\">",
"      Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/14\">",
"      Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/15\">",
"      Zucman D, Truchis Pd, Majerholc C, et al. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007; 45:1.",
"     </a>",
"    </li>",
"    <li>",
"     DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents December 1, 2009. www.AIDSinfo.nih.gov (Accessed on October 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/17\">",
"      Chui CK, Brumme ZL, Brumme CJ, et al. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Clin Infect Dis 2007; 44:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/18\">",
"      Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008; 46:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/19\">",
"      Waters LJ, Mandalia S, Gazzard B, Nelson M. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. AIDS 2007; 21:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/20\">",
"      Reisler RB, Murphy RL, Redfield RR, Parker RA. Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned. J Acquir Immune Defic Syndr 2005; 39:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/21\">",
"      Smith CJ, Olsen CH, Mocroft A, et al. The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. AIDS 2008; 22:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/22\">",
"      Maida I, Garcia-Gasco P, Sotgiu G, et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008; 13:103.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm199343.htm (Accessed on October 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/24\">",
"      Herlitz LC, Mohan S, Stokes MB, et al. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 2010; 78:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/25\">",
"      Martin-Carbonero L, Soriano V. New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients. J Antimicrob Chemother 2010; 65:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/26\">",
"      Mueller NJ, Fux CA, Ledergerber B, et al. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS 2010; 24:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/27\">",
"      Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/28\">",
"      Lodwick RK, Smith CJ, Youle M, et al. Stability of antiretroviral regimens in patients with viral suppression. AIDS 2008; 22:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/29\">",
"      Carr DF, Chaponda M, Jorgensen AL, et al. Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population. Clin Infect Dis 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/30\">",
"      Mehta U, Maartens G. Is it safe to switch between efavirenz and nevirapine in the event of toxicity? Lancet Infect Dis 2007; 7:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/31\">",
"      Dodi F, Alessandrini A, Camera M, et al. Stevens-Johnson syndrome in HIV patients treated with nevirapine: two case reports. AIDS 2002; 16:1197.",
"     </a>",
"    </li>",
"    <li>",
"     Mocroft A, Lacombe K, Rockstroh J, et al. Risk of discontinuation of nevirapine due to toxicity in antiretroviral naive and experienced patients with high and low CD4 counts. IAS Toronto 2006 Abstract #THAB0104.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/33\">",
"      Kumarasamy N, Venkatesh KK, Devaleenal B, et al. Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting. J Acquir Immune Defic Syndr 2007; 45:598.",
"     </a>",
"    </li>",
"    <li>",
"     Cohen C, et al. XVIIIth International AIDS Conference, Vienna, Austria, 18-23 July 2010. Abstract THLBB206 (Accessed on June 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/35\">",
"      Chapman TM, Plosker GL, Perry CM. Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. Drugs 2004; 64:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/36\">",
"      Introcaso CE, Hines JM, Kovarik CL. Cutaneous toxicities of antiretroviral therapy for HIV: part II. Nonnucleoside reverse transcriptase inhibitors, entry and fusion inhibitors, integrase inhibitors, and immune reconstitution syndrome. J Am Acad Dermatol 2010; 63:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/37\">",
"      Lowenhaupt EA, Matson K, Qureishi B, et al. Psychosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz. Clin Infect Dis 2007; 45:e128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/38\">",
"      Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/39\">",
"      Gandhi M, Greenblatt RM, Bacchetti P, et al. A single-nucleotide polymorphism in CYP2B6 leads to &gt;3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. J Infect Dis 2012; 206:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/61/986/abstract/40\">",
"      Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 2007; 45:1230.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3797 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-2FACFC3B1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_61_986=[""].join("\n");
var outline_f0_61_986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ADHERENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLASS SPECIFIC SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NUCLEOSIDE ANALOGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Abacavir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Abacavir hypersensitivity reaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Screening for AHR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Emtricitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Lamivudine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Didanosine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Stavudine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Tenofovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Zidovudine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Efavirenz",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Nevirapine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4007170\">",
"      Rilpivirine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Delavirdine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Etravirine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROTEASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Atazanavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Darunavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Fosamprenavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Indinavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Lopinavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Nelfinavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Ritonavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Saquinavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Tipranavir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      FUSION INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Enfuvirtide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      CCR5 INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Maraviroc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      INTEGRASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Raltegravir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      PHARMACOGENOMICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3797\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3797|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/4/70\" title=\"table 1A\">",
"      ARV class adverse reactions I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/30/42476\" title=\"table 1B\">",
"      ARV class adverse reactions II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21049?source=related_link\">",
"      Abacavir hypersensitivity reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/51/9013?source=related_link\">",
"      Atazanavir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32918?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: CCR5 antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3370?source=related_link\">",
"      Considerations prior to initiating antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/26/33189?source=related_link\">",
"      Darunavir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=related_link\">",
"      Delavirdine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=related_link\">",
"      Didanosine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=related_link\">",
"      Drugs and the liver: Patterns of drug-induced liver injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=related_link\">",
"      Efavirenz: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=related_link\">",
"      Emtricitabine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7205?source=related_link\">",
"      Enfuvirtide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=related_link\">",
"      Epidemiology of cardiovascular disease and risk factors in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/56/29577?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and treatment of HIV-associated peripheral neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35864?source=related_link\">",
"      Epidemiology, pathogenesis and clinical features of HIV-associated neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/3/63?source=related_link\">",
"      Evaluation of abdominal pain in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/5/32853?source=related_link\">",
"      Fosamprenavir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/28/3525?source=related_link\">",
"      Indinavir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=related_link\">",
"      Lamivudine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=related_link\">",
"      Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=related_link\">",
"      Nevirapine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=related_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/31/15861?source=related_link\">",
"      Patient information: Initial treatment of HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/44/22210?source=related_link\">",
"      Patient information: Starting treatment for HIV (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/56/2946?source=related_link\">",
"      Patient information: Tips for taking HIV medications (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=related_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/35/5686?source=related_link\">",
"      Ritonavir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/34/21029?source=related_link\">",
"      Saquinavir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=related_link\">",
"      Stavudine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=related_link\">",
"      Tenofovir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=related_link\">",
"      Tipranavir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=related_link\">",
"      Zidovudine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_61_987="Clinician factors difficult patients";
var content_f0_61_987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinician factors associated with experiencing more patients as difficult",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Little psychosocial training",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biomedical, rather than biopsychosocial, orientation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of personal awareness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fewer years out of training",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female gender",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Higher perceived workload",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lower job satisfaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of communication skills training",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_61_987=[""].join("\n");
var outline_f0_61_987=null;
var title_f0_61_988="JSGE criteria for EMR";
var content_f0_61_988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Japanese Society for Gastroenterological Endoscopy criteria for endoscopic mucosal resection (EMR) of early endoluminal cancers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cancer",
"       </td>",
"       <td class=\"subtitle1\">",
"        JSGE type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Criteria for EMR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Early gastric cancer",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        Less than or equal to 2 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IIb and IIc",
"       </td>",
"       <td>",
"        Less than or equal to 1 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intestinal type adenocarcinoma",
"       </td>",
"       <td>",
"        Limited to the mucosa",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Esophageal cancer",
"       </td>",
"       <td rowspan=\"3\">",
"        I, IIa, IIb, IIc",
"       </td>",
"       <td>",
"        Diameter of less than or equal to 2 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Involvement of less than one-third of the circumference of the esophageal wall",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limitation to the mucosa of the esophagus",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        Colon cancer",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        Less than 3 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        Less than 3 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        Less than 5 mm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IIc + IIa",
"       </td>",
"       <td>",
"        Less than 1 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IIa + IIc",
"       </td>",
"       <td>",
"        Less than 1 cm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        Less than 3 cm",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Raju GS, Waxman I. High-frequency US probe sonography-assisted endoscopic mucosal resection. Gastrointest Endosc 2000; 52:S39.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_61_988=[""].join("\n");
var outline_f0_61_988=null;
var title_f0_61_989="Management of pediatric lead poisoning";
var content_f0_61_989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidance for treatment actions for pediatric lead poisoning according to blood lead level (BLL)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Blood lead level (microg/dL)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment actions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        &lt;10",
"       </td>",
"       <td>",
"        Provide lead education and regular developmental/behavioral surveillance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reassess or rescreen in&nbsp;one year, or sooner if the child is younger than two years, was tested at the onset of warm weather, is at high risk for lead exposure, or the exposure sources have changed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        10 - 14",
"       </td>",
"       <td>",
"        Provide lead education and regular developmental/behavioral surveillance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide follow-up testing within one month, then every&nbsp;three to&nbsp;four months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        15 - 19",
"       </td>",
"       <td>",
"        Provide lead education and regular developmental/behavioral surveillance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide follow-up testing within one month, then every&nbsp;three to four months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Refer to social services",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Initiate professional environmental cleanup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Follow guidelines for 20 - 44 g/dL if BLL remains &ge;15 microg/dL (on two samples obtained at least three months apart)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        20 - 44",
"       </td>",
"       <td>",
"        Provide lead education and regular developmental/behavioral surveillance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Refer to clinical center specializing in lead poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide case management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide both clinical and environmental management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ensure lead hazard control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider treating with DMSA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"8\">",
"        45 - 69",
"       </td>",
"       <td>",
"        Provide lead education",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Refer to clinical center specializing in lead poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide coordination of care",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide diagnostic testing within 24 to 48 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perform clinical evaluation and management within 48 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide appropriate chelation therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perform aggressive environmental intervention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide follow-up testing at least once per month (in accordance with chelation therapy) and regular developmental/behavioral surveillance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        &ge;70",
"       </td>",
"       <td>",
"        This is a medical emergency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perform diagnostic testing immediately (samples shouldbe processed emergently)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hospitalize immediately and begin chelation therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Begin other activities as above",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Based upon confirmatory venousblood lead level.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Roberts JR, Reigart JR. Medical assessment and interventions. In: Managing Elevated Blood Lead Levels Among Young children:Recommendations from the Advisory Committee on Childhood Lead PoisoningPrevention. Centers for Disease Control and Prevention, Atlanta, GA, 2002.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_61_989=[""].join("\n");
var outline_f0_61_989=null;
var title_f0_61_990="Contents: Geriatric palliative care";
var content_f0_61_990=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?43/6/44141\">",
"       Geriatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Geriatric palliative care",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Geriatric palliative care",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/60/38858\">",
"           Assessment and management of depression in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/37/2650\">",
"           End of life considerations for heart failure patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/1/19477\">",
"           Ethical considerations in effective pain management at the end of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/63/44024\">",
"           Ethical issues near the end of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/12/24778\">",
"           Euthanasia and physician assisted suicide",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/29/31190\">",
"           Grief and bereavement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/16/32008\">",
"           Hospice: Philosophy of care and appropriate utilization in the United States",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/8/14473\">",
"           Legal aspects of end of life care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/52/28490\">",
"           Overview of comprehensive patient assessment in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/7/35962\">",
"           Overview of managing common non-pain symptoms in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/37/12890\">",
"           Pain assessment and management in the last weeks of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/6/29801\">",
"           Palliative care: Benefits, services, and models of care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/23/20855\">",
"           Palliative care: Issues specific to geriatric patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/4/29769\">",
"           Psychosocial issues at the end of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/15/41208\">",
"           Religion, spirituality, and end of life care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/11/4280\">",
"           Sexuality in palliative care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/6/39015\">",
"           Survival estimates in advanced cancer",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-426384BF11-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f0_61_990=[""].join("\n");
var outline_f0_61_990=null;
var title_f0_61_991="Pelagia noctiluca specimen";
var content_f0_61_991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pelagia noctiluca specimen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pelagia noctiluca specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Junghanss, T, Bodio, M. Medically important venomous animals: Biology, prevention, first aid, and clinical management. CID 2006; 32:1309. Copyright &copy; 2006 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_61_991=[""].join("\n");
var outline_f0_61_991=null;
